var title_f4_22_4448="Pediatric palpitations algorithm";
var content_f4_22_4448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Pediatric palpitations algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 704px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram; SVT: supraventricular tachycardia; VT: ventricular tachycardia; WPW: Wolff-Parkinson-White syndrome; SA: sinoatrial; ARF: acute rheumatic fever; PVC: premature ventricular contraction; PAC: premature atrial contraction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4448=[""].join("\n");
var outline_f4_22_4448=null;
var title_f4_22_4449="Intraarticular injection";
var content_f4_22_4449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraarticular shoulder injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopy is recommended to perform this procedure in obese patients. The patient assumes a sitting position with the shoulder relaxed. The humeral head, coracoid process, and acromioclavicular (AC) joint are located and marked. The point of entry is 1/2\" below the coracoid process. The angle of entry is 10 to 20 degrees up and out, aligned with the AC joint. A 3 1/2\", 22-gauge needle is used to a depth of 2 to 2 1/2\". Ethyl chloride is sprayed on the skin. Local anesthetic is placed at the pectoralis fascia (1 mL) and, the subscapularis fascia (1 mL), and intraarticularly (1 to 2 mL). 1 mL of triamcinolone acetonide (40 mg/mL) is then injected intraarticularly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4449=[""].join("\n");
var outline_f4_22_4449=null;
var title_f4_22_4450="CT NPH";
var content_f4_22_4450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT NPH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note placement of intraventricular shunt in the lateral ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4450=[""].join("\n");
var outline_f4_22_4450=null;
var title_f4_22_4451="Patient information: Latest medicines for hepatitis C (The Basics)";
var content_f4_22_4451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/46/41698\">",
"         Patient information: Hepatitis A (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/41/26258\">",
"         Patient information: Hepatitis B (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/35/30258\">",
"         Patient information: Treatment for hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/61/22483\">",
"         Patient information: Hepatitis A (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/45/31447\">",
"         Patient information: Hepatitis B (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/4/17478\">",
"         Patient information: Hepatitis C (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Latest medicines for hepatitis C (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/latest-medicines-for-hepatitis-c-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H96403975\">",
"      <span class=\"h1\">",
"       What are the latest medicines used to treat hepatitis C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The latest medicines for treating hepatitis C are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"         Boceprevir",
"        </a>",
"        (brand name: Victrelis",
"        <sup>",
"         TM",
"        </sup>",
"        )",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"         Telaprevir",
"        </a>",
"        (brand name: Incivek",
"        <sup>",
"         TM",
"        </sup>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These medicines were approved in May of 2011, so people treated before then would not have gotten them. These medicines work in people with type 1 hepatitis C, which is 1 of the most common types. Your doctor can do a blood test to find out what type you have.",
"     </p>",
"     <p>",
"      Compared with the medicines that have been used until now,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       boceprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      greatly increase the chances of curing a person with type 1 hepatitis C. But they work well only in people who take them exactly as directed. Boceprevir and telaprevir must be taken 3 times a day with food that has some fat in it. Each dose must be taken about 8 hours apart.",
"     </p>",
"     <p>",
"      If your doctor puts you on",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      , he or she will also put you on 2 other medicines, called peginterferon and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Peginterferon comes in a shot that you give yourself once a week. Ribavirin comes in pills that you take twice a day with food.",
"     </p>",
"     <p>",
"      It is very important that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take ALL your medicines exactly how your doctor or nurse tells you to",
"       </li>",
"       <li>",
"        Never skip doses",
"       </li>",
"       <li>",
"        Never stop any of your medicines unless your doctor or nurse tells you to",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96403982\">",
"      <span class=\"h1\">",
"       What happens if I do not take these medicines as directed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take these medicines the wrong way, you can end up doing yourself more harm than good. In people who skip doses or do not take all 3 different medicines, the hepatitis C virus can quickly become &ldquo;resistant.&rdquo; That means that the virus learns to outsmart the medicines, and so the medicines will not work. To help you remember to take all of your medicines at the right time, use special reminders called &ldquo;memory aids.&rdquo; For instance, use a &ldquo;talking&rdquo; pill box or a wrist watch that can be set to tell you whenever it&rsquo;s time to take your pills.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96403989\">",
"      <span class=\"h1\">",
"       What side effects can boceprevir or telaprevir cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These medicines can cause several side effects, but not everyone gets them all. The side effects of the 2 medicines are different but can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Anemia &mdash; This is a condition that makes you feel tired and weak and can cause headaches. People with anemia have too few red blood cells, so their blood cannot carry as much oxygen as the body needs. (Side effects can also include other blood cell problems, but anemia is the most common.)",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"       <li>",
"        Rash &mdash; The rash can be mild; sometimes it can be severe.",
"       </li>",
"       <li>",
"        Itching &mdash; People can have itching with or without a rash.",
"       </li>",
"       <li>",
"        Bitter taste in your mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hepatitis C medicines can also cause serious problems when they are taken with certain other medicines. This is called a &ldquo;drug interaction.&rdquo; To prevent problems due to drug interactions, review a list of all of your medicines (including herbal and non-prescription medicines) with your doctor whenever you start a new medicine. You can find an example of this kind of list at the following web site:",
"      <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/ucm079489.htm\">",
"       www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96403996\">",
"      <span class=\"h1\">",
"       What should I do if I get side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get any side effects that bother you, tell your doctor or nurse. In very rare cases, people need to stop taking their medicines because of severe rash or anemia. But DO NOT STOP TAKING YOUR MEDICINES because of side effects until you speak with your doctor or nurse. Only he or she can really tell if you need to stop the medicines.",
"     </p>",
"     <p>",
"      If you get a rash, your doctor or nurse will want to see your skin so he or she can decide how bad the rash is. He or she will also want to know right away if you start feeling light-headed or extremely weak or breathless. These can be signs of severe anemia.",
"     </p>",
"     <p>",
"      It is unlikely that your doctor or nurse will want to stop your medicines. Instead, he or she will probably be able to give you other medicines to make your side effects go away or get better. For example, if you are itchy, your doctor or nurse might give you medicines to relieve itch. If you have anemia, your doctor might lower the number of",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"       ribavirin",
"      </a>",
"      pills you are taking, since this medicine can also cause anemia.",
"     </p>",
"     <p>",
"      The point is, there are ways to deal with side effects so that you are comfortable enough to keep taking your medicines. But even if you have a little discomfort, you might decide the side effects are worth it for the chance of a cure. Remember, you only need to stay on",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      for a matter of months. After that, you might be cured of your infection and not need any medicines.",
"     </p>",
"     <p>",
"      This article has basic information on the latest medicines used to treat hepatitis C. For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines, and what to do if you forget to take a dose at the right time. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods. You should also ask your pharmacist for the FDA Medication Guides that come with the medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96404003\">",
"      <span class=\"h1\">",
"       How long will I need to take hepatitis C medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how your body responds to the medicines. Most people need to take medicines for several months, but some people might need to take them for about a year.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96404010\">",
"      <span class=\"h1\">",
"       Is there anyone who should not take hepatitis C medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people should not take the medicines used to treat hepatitis C, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pregnant women",
"       </li>",
"       <li>",
"        Women who are trying to get pregnant or who are not using a reliable form of birth control",
"       </li>",
"       <li>",
"        Men who are trying to get someone pregnant or who are not using a reliable form of birth control",
"       </li>",
"       <li>",
"        People with depression and certain other medical conditions",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H96404108\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       Patient information: Hepatitis B (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=see_link\">",
"       Patient information: Hepatitis A (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=see_link\">",
"       Patient information: Treatment for hepatitis C (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       Patient information: Hepatitis C (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       Patient information: Hepatitis B (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=see_link\">",
"       Patient information: Hepatitis A (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/22/4451?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16223 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4451=[""].join("\n");
var outline_f4_22_4451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96403975\">",
"      What are the latest medicines used to treat hepatitis C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96403982\">",
"      What happens if I do not take these medicines as directed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96403989\">",
"      What side effects can boceprevir or telaprevir cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96403996\">",
"      What should I do if I get side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96404003\">",
"      How long will I need to take hepatitis C medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96404010\">",
"      Is there anyone who should not take hepatitis C medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96404108\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/61/22483?source=related_link\">",
"      Patient information: Hepatitis A (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/46/41698?source=related_link\">",
"      Patient information: Hepatitis A (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=related_link\">",
"      Patient information: Treatment for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4452="Nail lichen planus longitudinal fissuring";
var content_f4_22_4452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Longitudinal nail fissuring caused by lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4452=[""].join("\n");
var outline_f4_22_4452=null;
var title_f4_22_4453="Surgical termination of pregnancy: First trimester";
var content_f4_22_4453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical termination of pregnancy: First trimester",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Lee P Shulman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Frank W Ling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4453/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/22/4453/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction curettage is the most commonly used method of pregnancy termination in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The procedure, also referred to as dilation and evacuation, is usually performed between the 7th and 13th menstrual weeks. According to the Centers for Disease Control, over 96 percent of abortions in the United States in 2001 were performed by suction curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/3\">",
"     3",
"    </a>",
"    ]. The procedure does not require hospitalization except in women with medical or surgical disorders that place them at higher surgical risk.",
"   </p>",
"   <p>",
"    Suction curettage of the uterus in the first trimester will be reviewed here. General issues regarding preoperative evaluation and patient preparation, anesthesia, complications, and follow-up, and second trimester pregnancy termination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation of the cervix is usually necessary to allow insertion of instruments and removal of bulky uterine contents. However, very early pregnancies (eg, less than seven weeks of gestation) may not require cervical dilation. In pregnancies 7 to 13 weeks, the endocervical canal can either be dilated manually or osmotic dilators or prostaglandins can be used to gradually dilate the cervix. The latter two methods require a few hours to work and may involve additional patient visits; therefore, many practitioners and clinics due not use them in the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pregnancy termination\", section on 'Cervical preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CURETTAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Manual vacuum aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vacuum aspiration is generally performed with an electric suction device, however, it may also be performed with a manual aspirator. At less than 10 weeks of gestation, it appears that manual vacuum aspiration (MVA) is as safe and effective as electric vacuum aspiration (EVA), and may result in less pain and blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A systematic review that compared MVA to EVA for termination of pregnancy at less than 10 weeks reported no significant differences between the two methods for complete abortion rate or patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both EVA and MVA produce about 60 mmHg of suction, but manual aspiration has the advantage of being quieter. Patients are often disturbed by the noise of the electric device [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast to an electric suction device, the manual vacuum aspirator is more portable, inexpensive, and does not require electricity, thereby making it a favorable choice for low-resource settings.",
"   </p>",
"   <p>",
"    The manual vacuum aspirator is a hand-operated, 50 or 60 mL syringe in which vacuum is produced retracting a plunger at the other. The syringe is connected to the Luerlock end of either a 3 to 4 mm rigid (eg, Karman cannula (",
"    <a class=\"graphic graphic_picture graphicRef53042 \" href=\"UTD.htm?7/37/7760\">",
"     picture 1",
"    </a>",
"    )) or 6 mm flexible cannula. The products of conception are aspirated by rapidly withdrawing and depressing the syringe plunger 20 to 30 times. The cannula is moved in and out and simultaneously rotated in a 360 degree arc. The catheter is removed under continuous maximum negative pressure when aspiration of intrauterine contents appears to be complete. Suction will decrease when the syringe is 80 percent full.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electric vacuum aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electric vacuum aspiration can be used for terminations at all gestational ages. To perform this procedure, a rigid curved suction curette (",
"    <a class=\"graphic graphic_picture graphicRef60556 \" href=\"UTD.htm?25/38/26210\">",
"     picture 2",
"    </a>",
"    ) is inserted into the uterine cavity without suction. The diameter of the curette in millimeters equals the gestational age in weeks of the pregnancy (ie, a #8 suction curette [8-mm diameter] would be used to evacuate an eight-week [menstrual weeks] size uterus).",
"   </p>",
"   <p>",
"    The curette is connected to the collection vessel with transparent polyethylene tubing after the tip of the curette is within the uterine cavity. Suction is then applied using an aspiration device. The curette is rotated side to side (not in and out) in a wide arc during tissue aspiration; this reduces the likelihood of instrument perforation of the uterine fundus (",
"    <a class=\"graphic graphic_figure graphicRef78988 \" href=\"UTD.htm?14/62/15332\">",
"     figure 1",
"    </a>",
"    ). When no further tissue can be aspirated, the curette is withdrawn under continuous suction.",
"   </p>",
"   <p>",
"    A metal curette may then be used to gently scrape the endometrial cavity to verify that all products of conception have been removed (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Sharp curettage'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sharp curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vacuum aspiration of uterine contents is preferable to sharp curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/7\">",
"     7",
"    </a>",
"    ], although sharp curettage may be performed at the end of the procedure to assess the uterine cavity for remaining tissue. In a well-designed trial, women with incomplete abortion were randomly assigned to vacuum aspiration or sharp curettage. Compared to sharp curettage, vacuum aspiration was associated with statistically significantly decrease in blood loss, less pain, and shorter duration of procedure. No difference was found in need for re-evacuation. Serious complications, such as uterine perforation, were rare in both groups.",
"   </p>",
"   <p>",
"    The sharp metal curette used to check for retained tissue should be the largest curette that easily passes through the cervical canal. An empty uterus contracts and is characterized by a gritty sensation during curettage. If products remain within the cavity after sharp curettage, suction curettage is repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/8\">",
"     8",
"    </a>",
"    ]. Placing the abdominal hand on the fundus stabilizes the uterus and enhances depth perception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXAMINATION OF TISSUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnancies less than 7 weeks of gestation, the aspirate is examined by placing it in a small amount of sterile water or saline, washing away adherent blood and clots, and looking for fetal membranes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fronds indicative of placental villi [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/9\">",
"     9",
"    </a>",
"    ]. Backlighting through a glass dish is useful for identifying these structures. Presence of products of conception is highly predictive of a complete abortion and routine examination by a pathologist is probably not necessary in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, many state regulations require that all of the tissue obtained should be sent to the pathology department for evaluation, although the need for this practice has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/10\">",
"     10",
"    </a>",
"    ]. For pregnancies &ge;7 weeks of gestation, the products of conception should be examined in the procedure room to verify the presence of both villi and fetal parts; ideally a cranium, four extremities, and a rib cage are identifiable by the late first trimester. Gestational age should be confirmed and recorded after measuring the fetal foot length (",
"    <a class=\"graphic graphic_table graphicRef64496 \" href=\"UTD.htm?5/54/5995\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Failure to obtain a sufficient volume of tissue necessitates repeating the procedure. Absence of products of conception may indicate an incomplete procedure or an ectopic pregnancy; diagnostic measures (eg, ultrasound examination, serial human chorionic gonadotropin (hCG) assays) should be initiated in such cases. If an ongoing intrauterine pregnancy is diagnosed, the procedure can be attempted again with ultrasound guidance (if a sac can be visualized) or in one or two weeks when the sac is larger, or, in some cases, a medical abortion can be offered.",
"   </p>",
"   <p>",
"    Women with suspected ectopic pregnancies should be monitored carefully with serial hCG levels; follow-up within 24 to 48 hours is obligatory, and all of these women must be cautioned about the symptoms of ectopic pregnancy rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to remember that early pregnancies may be complicated by complete or partial mole, which require specialized follow-up because some cases progress to malignant forms of gestational trophoblastic disease (GTD). It has been estimated that four of 1000 women having early termination of pregnancy have a molar pregnancy",
"    <span class=\"nowrap\">",
"     (1/1000",
"    </span>",
"    complete mole,",
"    <span class=\"nowrap\">",
"     3/1000",
"    </span>",
"    partial mole). In one study, 15 such women were diagnosed one to 12 months after their abortion procedure and thus did not undergo standard GTD monitoring for",
"    <span class=\"nowrap\">",
"     recurrent/persistent",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to 36 women diagnosed at the time of pregnancy termination, the women with delayed diagnosis of GTD were at high risk of developing a life-threatening hemorrhage or needing surgical intervention or chemotherapy. The possibility of GTD should be considered if menses have not returned by six weeks after the procedure or persistent vaginal bleeding or uterine enlargement occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care and follow-up are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of pregnancy termination\", section on 'Postoperative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of pregnancy termination\", section on 'Follow up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First trimester suction curettage is the safest method for surgical pregnancy termination; second-trimester techniques of extraction, intraamniotic instillation of abortifacients, and hysterotomy or hysterectomy all carry higher mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4453/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Complications of pregnancy termination, such as hemorrhage, uterine perforation, infection, and retained products of conception, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of pregnancy termination\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=see_link\">",
"       \"Patient information: Abortion (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"       \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osmotic dilators can be used to reduce the risk of cervical lacerations in pregnancies of 7 to 13 weeks of gestation, but require a few hours to work and may require additional patient visits. Therefore, many practitioners and clinics do not use them in the first trimester. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suction curettage is the most commonly used method of first trimester pregnancy termination in the United States. Suction curettage results in reduced pain and blood loss, and shorter procedure time than sharp curettage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Curettage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies &lt;10 weeks, electric or manual suction curettage can be used. Manual suction is safe and effective, and may decrease intraoperative pain or bleeding. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Manual vacuum aspiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aspirate is examined by placing it in a small amount of sterile water or saline, washing away adherent blood and clots, and looking for fetal membranes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fronds indicative of placental villi. Backlighting through a glass dish is useful for identifying these structures. Absence of products of conception may indicate an incomplete procedure or an ectopic pregnancy; further diagnostic measures should be initiated in such cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Examination of tissue'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/1\">",
"      Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril 1986; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Methods of midtrimester abortion. ACOG technical bulletin #109. American College of Obstetricians and Gynecologists, Washington, DC 1987.",
"    </li>",
"    <li>",
"     www.cdc.gov/mmwr/preview/mmwrhtml/ss5309a1.htm (Accessed 3/8/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/4\">",
"      Wen J, Cai QY, Deng F, Li YP. Manual versus electric vacuum aspiration for first-trimester abortion: a systematic review. BJOG 2008; 115:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/5\">",
"      Goldberg AB, Dean G, Kang MS, et al. Manual versus electric vacuum aspiration for early first-trimester abortion: a controlled study of complication rates. Obstet Gynecol 2004; 103:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/6\">",
"      Dean G, Cardenas L, Darney P, Goldberg A. Acceptability of manual versus electric aspiration for first trimester abortion: a randomized trial. Contraception 2003; 67:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/7\">",
"      Verkuyl DA, Crowther CA. Suction v. conventional curettage in incomplete abortion. A randomised controlled trial. S Afr Med J 1993; 83:13.",
"     </a>",
"    </li>",
"    <li>",
"     Shulman, LP, Elias, S, Simpson, JL. Induced abortion for genetic indications: techniques and complications. In: Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment, Milunsky, A (Ed), Johns Hopkins University Press, Baltimore 1992. p.721.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/9\">",
"      Munsick RA. Clinical test for placenta in 300 consecutive menstrual aspirations. Obstet Gynecol 1982; 60:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/10\">",
"      Paul M, Lackie E, Mitchell C, et al. Is pathology examination useful after early surgical abortion? Obstet Gynecol 2002; 99:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/11\">",
"      Heath V, Chadwick V, Cooke I, et al. Should tissue from pregnancy termination and uterine evacuation routinely be examined histologically? BJOG 2000; 107:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/12\">",
"      Seckl MJ, Gillmore R, Foskett M, et al. Routine terminations of pregnancy--should we screen for gestational trophoblastic neoplasia? Lancet 2004; 364:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/13\">",
"      Hodgson JE. Major complications of 20,248 consecutive first trimester abortions: problems of fragmented care. Adv Plan Parent 1975; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/14\">",
"      Nathanson BN. Ambulatory abortion: experience with 26,000 cases (July 1, 1970, to August 1, 1971). N Engl J Med 1972; 286:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4453/abstract/15\">",
"      Hodgson JE, Portmann KC. Complications of 10,453 consecutive first-trimester abortions: a prospective study. Am J Obstet Gynecol 1974; 120:802.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3287 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-F7DA7CD4CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4453=[""].join("\n");
var outline_f4_22_4453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CURETTAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Manual vacuum aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electric vacuum aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sharp curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXAMINATION OF TISSUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3287|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/62/15332\" title=\"figure 1\">",
"      Abortion by suction curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3287|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/37/7760\" title=\"picture 1\">",
"      Karmen cannula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/38/26210\" title=\"picture 2\">",
"      Rigid plastic suction curette",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3287|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/54/5995\" title=\"table 1\">",
"      Fetal age by foot length",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=related_link\">",
"      Patient information: Abortion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4454="Light microscopy of Bartonella";
var content_f4_22_4454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy of bacillary angiomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin stain of skin biopsy sample in a patient with bacillary angiomatosis. The histology shows uniformly appearing plump cells; many of these cells line the lumina of vascular channels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David H Spach, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4454=[""].join("\n");
var outline_f4_22_4454=null;
var title_f4_22_4455="Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers";
var content_f4_22_4455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Ken D Hatch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4455/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/22/4455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1989, Dargent used the laparoscope to perform limited pelvic lymphadenectomy on women with cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, additional observational studies have established the feasibility, oncologic validity, and safety of laparoscopic pelvic and paraaortic node dissection in women with a variety of gynecologic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/2-10\">",
"     2-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General advantages of the laparoscopic approach are a decrease in operative time, less blood loss, shorter hospital stay, and reduction in total cost. The only randomized trial evaluating different approaches to pelvic lymphadenectomy compared laparoscopic to extraperitoneal or transperitoneal lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/11\">",
"     11",
"    </a>",
"    ]. The three techniques had similar complication rates, the laparoscopic approach took longer (75 versus 54 and 63 minutes, respectively) and fewer lymph nodes were resected (30 versus 35 and 36, respectively), but recovery was faster (hospitalization 3.1 versus 3.2 and 5.6 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of laparoscopy are most meaningful if subsequent laparotomy for treatment of the gynecologic malignancy is also avoided. As an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhanced staging of cervical carcinoma: Laparoscopic lymphadenectomy provides better information than imaging studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/12\">",
"       12",
"      </a>",
"      ]. Node-negative women may be treated by laparoscopic or vaginal radical hysterectomy performed either simultaneously (based upon frozen section results [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/13\">",
"       13",
"      </a>",
"      ]) or secondarily after routine pathologic examination of the pelvic nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/8,9,14-17\">",
"       8,9,14-17",
"      </a>",
"      ]. Node-positive women are generally considered for radiotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy. Knowledge of periaortic node positivity allows for individualization of the radiation field. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link\">",
"       \"Laparoscopic approach to hysterectomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laparoscopic staging of cervical carcinoma is also useful when radical trachelectomy is planned.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I and some stage II endometrial cancers can be staged and then treated by total hysterectomy, bilateral salpingo-oophorectomy (BSO), and pelvic lymphadenectomy using only a laparoscopic approach or the hysterectomy-BSO can be done vaginally [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/18-22\">",
"       18-22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link\">",
"       \"Laparoscopic approach to hysterectomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laparoscopic sentinel node mapping in women with early stage cervical [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/23-30\">",
"     23-30",
"    </a>",
"    ] or endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] is also being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/33\">",
"     33",
"    </a>",
"    ]. The benefits of sentinel lymph node procedures include: reduced operative time; reduced blood loss; reduction in nerve, blood vessel, and ureteral injuries; and increased identification of metastatic lymph nodes through ultra-staging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/33\">",
"     33",
"    </a>",
"    ]. It is not practical to do ultra-staging on the large number of lymph nodes retrieved by complete pelvic lymphadenectomy; however, it is feasible to examine targeted lymph nodes in this way. Another benefit of the sentinel lymph node technique is that it may identify lymph nodes in areas that may not be dissected in a standard lymphadenectomy.",
"   </p>",
"   <p>",
"    There have been 824 patients with cervical cancer reported in the literature who have had sentinel lymph node procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/33\">",
"     33",
"    </a>",
"    ]. Sentinel lymph nodes were identified in 84 percent of these patients. There were 161 (22 percent) positive lymph nodes, of which the sentinel lymph node technique detected 148, yielding a false-negative rate of 13 percent. Since grossly positive lymph nodes are often negative for both blue dye and radio-collide and contribute to the false-negative rate, it is recommended that patients with grossly positive nodes be excluded from sentinel node mapping. In addition, the parametrial lymph nodes are nearly impossible to detect with these techniques, but since they are removed with the radical hysterectomy, metastases to these nodes should not be missed. When these studies are re-analyzed accounting for grossly positive and parametrial nodes, the false-negative rate falls to less than 2 percent.",
"   </p>",
"   <p>",
"    Laparoscopy has been used for second look operations in ovarian cancer for a number of years; however, its value for staging ovarian cancer has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic staging has also been used for interval staging of women with pelvic malignancies who were incompletely staged at initial surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the bowel be collapsed during the laparoscopic lymphadenectomy so that proper exposure can be obtained. This is particularly important if the patient is obese and paraaortic lymphadenectomy is planned. Therefore, we place our patients on a clear liquid diet the day before the surgical procedure and evacuate the bowel using magnesium citrate or Go-Lytely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPERATIVE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned in a dorsal lithotomy position using stirrups to support the legs. There should be minimal external hip rotation and no part of the leg should receive excessive pressure from the stirrups. It is helpful to have adjustable stirrups that allow for conversion from the low lithotomy to a leg-flexed position for vaginal surgery. The arms are tucked at the side, an endotracheal tube is positioned, and a Foley catheter is placed in the bladder.",
"   </p>",
"   <p>",
"    The principles of laparoscopic surgery are the same as those of laparotomy: there must be adequate exposure, identification of the anatomy, and removal of the appropriate tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trocar placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trocar is inserted into the umbilicus if the patient has not had a previous midline incision. If there is a midline scar, then the left upper quadrant is insufflated and a 5 mm trocar inserted. The left upper quadrant approach for patients with previous midline incisions allows the laparoscope to be placed away from possible adhesions that can then be dissected from the umbilicus before placing a second, 10 mm trocar.",
"   </p>",
"   <p>",
"    Additional trocars are then positioned in the right and left lower quadrants and in the suprapubic area (",
"    <a class=\"graphic graphic_picture graphicRef57588 \" href=\"UTD.htm?34/3/34865\">",
"     picture 1",
"    </a>",
"    ). A laparoscope in the suprapubic port site can help with packing the bowel or in dissecting adhesions from around the umbilical port.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bowel is carefully packed into the upper abdomen so that adequate exposure of the paraaortic area and pelvis can be obtained. Sponges or minilaparotomy packs can be placed around loops of bowel to aid in exposure and to blot small amounts of blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymphadenectomies are best performed by the surgeon on the side opposite the side of dissection (eg, the surgeon on the patient's right side dissects the left pelvic lymph nodes). For endometrial cancer, a partial lymphadenectomy (lymph node sampling) is performed: the lymph nodes removed are those medial to the external iliac and superior to the obturator nerve. For cervical cancer, a complete lymphadenectomy is performed, including the lymph nodes between the iliac vessels and the psoas muscle, and the obturator space is dissected in its entirety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Paraaortic nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paraaortic lymphadenectomy is usually performed first. The landmarks are usually the reflection of the duodenum and inferior mesenteric vessel superiorly and the psoas muscles laterally. The ureter must be identified and placed on traction by the assistant to keep it out of the operative field. Both the right- and left-sided aortic lymph nodes are sampled. Variations in vascular anatomy are not uncommon in this area; awareness of these variants and cautious dissection is advised to avoid vascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peritoneum is incised between the sigmoid mesentery and the mesentery of the cecum (",
"    <a class=\"graphic graphic_picture graphicRef79385 \" href=\"UTD.htm?39/12/40129\">",
"     picture 2",
"    </a>",
"    ). The paraaortic lymph node chain is isolated and dissected using either monopolar surgery, bipolar surgery, ultrasonic cutting and coagulation device (eg, Harmonic Scalpel&reg;), or the argon beam coagulator (",
"    <a class=\"graphic graphic_picture graphicRef51405 graphicRef61111 graphicRef72885 graphicRef53957 graphicRef65768 graphicRef75527 graphicRef50441 \" href=\"UTD.htm?43/23/44410\">",
"     picture 3A-G",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Common iliac nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal common iliac lymph nodes are dissected through a retroperitoneal incision extending from the paraaortic lymph nodes down to the middle common iliac lymph nodes (",
"    <a class=\"graphic graphic_picture graphicRef65246 \" href=\"UTD.htm?2/15/2291\">",
"     picture 4",
"    </a>",
"    ). The remaining common iliac lymph nodes are dissected through the incision for the pelvic lymphadenectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pelvic nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic lymph nodes are exposed by dividing the round ligaments and retracting the obliterated umbilical artery medially, thus opening the entire lateral pelvic space (",
"    <a class=\"graphic graphic_picture graphicRef65238 graphicRef68003 graphicRef58377 \" href=\"UTD.htm?8/61/9177\">",
"     picture 5A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The disease (cervical or endometrial cancer) and clinical circumstances determine the extent of the pelvic lymphadenectomy, as discussed above. To perform pelvic lymph node sampling, the lymph nodes are removed medial to the external iliac and anterior to the obturator nerve (",
"    <a class=\"graphic graphic_picture graphicRef54235 graphicRef63994 graphicRef75760 graphicRef56870 graphicRef68645 \" href=\"UTD.htm?38/2/38954\">",
"     picture 6A-E",
"    </a>",
"    ). For a complete lymphadenectomy, the lymph nodes are also removed from between the iliac vessels and the psoas muscle, and from the obturator fossa (",
"    <a class=\"graphic graphic_picture graphicRef79071 graphicRef57188 graphicRef67137 \" href=\"UTD.htm?42/42/43688\">",
"     picture 7A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;All port sites 10 mm or larger should have the fascia and peritoneal layers closed to prevent herniation of bowel. Smaller peritoneal incisions are left open. Several instruments are available that pass the suture through the skin incision lateral to the port and back up on the opposite side to create a one layer closure. A local anesthetic is injected around the port sites to decrease postoperative pain. Drains are not used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are given liquids the day of surgery and the diet is advanced rapidly. Early ambulation is encouraged. The patient's progress is usually rapid with discharge within one or two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complication rate in large case series varies from 1 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adynamic ileus is unusual after laparoscopic surgery. Abdominal distention, worsening of pain, or vomiting must be taken seriously as these symptoms could be due to a bowel injury. The carbon dioxide used for insufflation should be absorbed within hours, so any free air on x-ray of the abdomen is highly suspicious of perforation. Vascular and urinary tract injuries can also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of laparoscopy for malignant disease are higher than for benign disease, and include port site metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/37\">",
"     37",
"    </a>",
"    ]. The rate depends upon the type of case, whether there had been previous pelvic surgery or adhesive disease (eg, endometriosis, pelvic inflammatory disease), and the experience of the surgeon.",
"   </p>",
"   <p>",
"    Data on complication rates from laparoscopic lymphadenectomy are inadequate due to small sample sizes, lack of adjustment for a learning curve, and confounding by combinations of and differences in procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Postoperative complications of wound infection, ileus, and fever occur, but at lower rates than after laparotomy. Herniation of omentum or bowel into the trocar sites is a complication unique to laparoscopy and occurred in 0.17 percent of 3560 laparoscopic operations in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/41\">",
"     41",
"    </a>",
"    ]. In another study of 19 cases of postlaparoscopy herniation from 11 institutions, no patient had a hernia through a port site smaller than 10 cm; therefore, it is recommended that all port sites greater than 10 mm be closed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/42\">",
"     42",
"    </a>",
"    ]. Conversion to open laparotomy is necessary in fewer than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/36,43,44\">",
"     36,43,44",
"    </a>",
"    ]. The most common reasons are obesity, bleeding, adhesions and intraperitoneal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. A series including 1000 patients reported postoperative lymphocyst formation in 7 percent; significant vascular, bowel, or urinary tract injury occurred in fewer than 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4455/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skills to manage gynecologic malignancies by laparoscopic techniques are acquired through a commitment on the surgeon's part to learn the technique. It requires up-to-date equipment and a team familiar with the procedures. Hands-on experience in an animal laboratory and proctored learning in the operating suite are highly recommended.",
"   </p>",
"   <p>",
"    Cellulitis following pelvic lymph node dissection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"     \"Cellulitis following pelvic lymph node dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The advantages of the laparoscopic approach to lymphadenectomy are a decrease in operative time, less blood loss, shorter hospital stay, and reduction in total cost. These benefits are most meaningful if subsequent laparotomy for treatment of the gynecologic malignancy is also avoided. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic lymphadenectomy is most commonly used for enhanced staging and treatment of cervical cancer and for staging and treatment of endometrial cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operative approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skills to manage gynecologic malignancies by laparoscopic techniques require up-to-date equipment, hands-on experience in an animal laboratory, proctored learning, and an operating team familiar with the procedures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operative approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest placing patients on a clear liquid diet the day before the surgical procedure and evacuating the bowel using magnesium citrate or Go-Lytely. This collapses the bowel, making it less likely to obstruct the operative field. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All port sites 10 mm or larger should have the fascia and peritoneal layers closed to prevent herniation of bowel. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Operative approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dargent D, Salvat J. Envahissenent ganglionnaire pelvien: place de la pelviscopie retroperitoneale, Medsi - McGraw-Hill, Paris 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/2\">",
"      Fowler JM, Carter JR, Carlson JW, et al. Lymph node yield from laparoscopic lymphadenectomy in cervical cancer: a comparative study. Gynecol Oncol 1993; 51:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/3\">",
"      Querleu D, LeBlanc E. Laparoscopic infrarenal paraaortic lymph node dissection for restaging of carcinoma of the ovary or fallopian tube. Cancer 1994; 73:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/4\">",
"      Spirtos NM, Schlaerth JB, Spirtos TW, et al. Laparoscopic bilateral pelvic and paraaortic lymph node sampling: an evolving technique. Am J Obstet Gynecol 1995; 173:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/5\">",
"      Possover M, Krause N, K&uuml;hne-Heid R, Schneider A. Value of laparoscopic evaluation of paraaortic and pelvic lymph nodes for treatment of cervical cancer. Am J Obstet Gynecol 1998; 178:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/6\">",
"      Possover M, Plaul K, Krause N, Schneider A. Left-sided laparoscopic para-aortic lymphadenectomy: anatomy of the ventral tributaries of the infrarenal vena cava. Am J Obstet Gynecol 1998; 179:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/7\">",
"      K&ouml;hler C, Tozzi R, Klemm P, Schneider A. Laparoscopic paraaortic left-sided transperitoneal infrarenal lymphadenectomy in patients with gynecologic malignancies: technique and results. Gynecol Oncol 2003; 91:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/8\">",
"      Spirtos NM, Eisenkop SM, Schlaerth JB, Ballon SC. Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy in patients with stage I cervical cancer: surgical morbidity and intermediate follow-up. Am J Obstet Gynecol 2002; 187:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/9\">",
"      Hertel H, K&ouml;hler C, Michels W, et al. Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol 2003; 90:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/10\">",
"      Gemignani ML, Curtin JP, Zelmanovich J, et al. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol Oncol 1999; 73:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/11\">",
"      Panici PB, Plotti F, Zullo MA, et al. Pelvic lymphadenectomy for cervical carcinoma: laparotomy extraperitoneal, transperitoneal or laparoscopic approach? A randomized study. Gynecol Oncol 2006; 103:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/12\">",
"      Hertel H, K&ouml;hler C, Elhawary T, et al. Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol 2002; 87:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/13\">",
"      Fanfani F, Ludovisi M, Zannoni GF, et al. Frozen section examination of pelvic lymph nodes in endometrial and cervical cancer: accuracy in patients submitted to neoadjuvant treatments. Gynecol Oncol 2004; 94:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/14\">",
"      Hatch KD, Hallum AV 3rd, Nour M. New surgical approaches to treatment of cervical cancer. J Natl Cancer Inst Monogr 1996; :71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/15\">",
"      Schneider A, Possover M, Kamprath S, et al. Laparoscopy-assisted radical vaginal hysterectomy modified according to Schauta-Stoeckel. Obstet Gynecol 1996; 88:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/16\">",
"      Renaud MC, Plante M, Roy M. Combined laparoscopic and vaginal radical surgery in cervical cancer. Gynecol Oncol 2000; 79:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/17\">",
"      Querleu D, Narducci F, Poulard V, et al. Modified radical vaginal hysterectomy with or without laparoscopic nerve-sparing dissection: a comparative study. Gynecol Oncol 2002; 85:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/18\">",
"      Gemignani, M, Curtin, J, Barakat, R, et al. Laparoscopic-assisted vaginal hysterectomy (LAVH) versus total abdominal hysterectomy (TAH) for endometrial adenocarcinoma: a comparison of clinical outcomes and hospital charges (abstract). Gynecol Oncol 1998; 68:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/19\">",
"      Eltabbakh GH. Analysis of survival after laparoscopy in women with endometrial carcinoma. Cancer 2002; 95:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/20\">",
"      Malur S, Possover M, Michels W, Schneider A. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer--a prospective randomized trial. Gynecol Oncol 2001; 80:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/21\">",
"      Holub Z, Jabor A, Bartos P, et al. Laparoscopic surgery for endometrial cancer: long-term results of a multicentric study. Eur J Gynaecol Oncol 2002; 23:305.",
"     </a>",
"    </li>",
"    <li>",
"     Hatch, KD. Clinical outcomes and long term survival after laparoscopic staging and hysterectomy for endometrial cancer (abstract). SGO 35th Annual Meeting, Feb. 9, 2004, San Diego.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/23\">",
"      Dargent D, Martin X, Mathevet P. Laparoscopic assessment of the sentinel lymph node in early stage cervical cancer. Gynecol Oncol 2000; 79:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/24\">",
"      Lantzsch T, Wolters M, Grimm J, et al. Sentinel node procedure in Ib cervical cancer: a preliminary series. Br J Cancer 2001; 85:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/25\">",
"      Malur S, Krause N, K&ouml;hler C, Schneider A. Sentinel lymph node detection in patients with cervical cancer. Gynecol Oncol 2001; 80:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/26\">",
"      Levenback C, Coleman RL, Burke TW, et al. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol 2002; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/27\">",
"      Buist MR, Pijpers RJ, van Lingen A, et al. Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer. Gynecol Oncol 2003; 90:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/28\">",
"      Lambaudie E, Collinet P, Narducci F, et al. Laparoscopic identification of sentinel lymph nodes in early stage cervical cancer: prospective study using a combination of patent blue dye injection and technetium radiocolloid injection. Gynecol Oncol 2003; 89:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/29\">",
"      Dargent D, Enria R. Laparoscopic assessment of the sentinel lymph nodes in early cervical cancer. Technique--preliminary results and future developments. Crit Rev Oncol Hematol 2003; 48:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/30\">",
"      Plante M, Renaud MC, T&ecirc;tu B, et al. Laparoscopic sentinel node mapping in early-stage cervical cancer. Gynecol Oncol 2003; 91:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/31\">",
"      Holub Z, Jabor A, Kliment L. Comparison of two procedures for sentinel lymph node detection in patients with endometrial cancer: a pilot study. Eur J Gynaecol Oncol 2002; 23:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/32\">",
"      Gargiulo T, Giusti M, Bottero A, et al. Sentinel Lymph Node (SLN) laparoscopic assessment early stage in endometrial cancer. Minerva Ginecol 2003; 55:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/33\">",
"      Hauspy J, Beiner M, Harley I, et al. Sentinel lymph nodes in early stage cervical cancer. Gynecol Oncol 2007; 105:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/34\">",
"      Spirtos NM, Eisekop SM, Boike G, et al. Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am J Obstet Gynecol 2005; 193:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/35\">",
"      Klemm P, Fr&ouml;ber R, K&ouml;hler C, Schneider A. Vascular anomalies in the paraaortic region diagnosed by laparoscopy in patients with gynaecologic malignancies. Gynecol Oncol 2005; 96:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/36\">",
"      Querleu D, Leblanc E, Cartron G, et al. Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. Am J Obstet Gynecol 2006; 195:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/37\">",
"      Abu-Rustum N, Barakat R, Curtin J. Laparoscopic complications in gynecologic surgery for benign or malignant disease (abstract). Gynecol Oncol 1998; 68:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/38\">",
"      Altgassen C, Possover M, Krause N, et al. Establishing a new technique of laparoscopic pelvic and para-aortic lymphadenectomy. Obstet Gynecol 2000; 95:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/39\">",
"      Scribner DR Jr, Walker JL, Johnson GA, et al. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol 2001; 82:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/40\">",
"      Dottino PR, Tobias DH, Beddoe A, et al. Laparoscopic lymphadenectomy for gynecologic malignancies. Gynecol Oncol 1999; 73:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/41\">",
"      Kadar N, Reich H, Liu CY, et al. Incisional hernias after major laparoscopic gynecologic procedures. Am J Obstet Gynecol 1993; 168:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/42\">",
"      Boike GM, Miller CE, Spirtos NM, et al. Incisional bowel herniations after operative laparoscopy: a series of nineteen cases and review of the literature. Am J Obstet Gynecol 1995; 172:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/43\">",
"      Abu-Rustum NR, Chi DS, Sonoda Y, et al. Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. Gynecol Oncol 2003; 89:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4455/abstract/44\">",
"      K&ouml;hler C, Klemm P, Schau A, et al. Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies. Gynecol Oncol 2004; 95:52.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3182 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4455=[""].join("\n");
var outline_f4_22_4455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPERATIVE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trocar placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Paraaortic nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Common iliac nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pelvic nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3182|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34865\" title=\"picture 1\">",
"      Abdominal port position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/12/40129\" title=\"picture 2\">",
"      Right paraaortic space opened",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/20/26946\" title=\"picture 3A\">",
"      Paraaortic node dissection1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/59/10162\" title=\"picture 3B\">",
"      Paraaortic node dissection2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/18/6435\" title=\"picture 3C\">",
"      Paraaortic node dissection3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/5/9300\" title=\"picture 3D\">",
"      Paraaortic node dissection4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/63/23540\" title=\"picture 3E\">",
"      Paraaortic node dissection5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/30/6627\" title=\"picture 3F\">",
"      Paraaortic node dissection6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2292\" title=\"picture 3G\">",
"      Paraaortic node dissection7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2291\" title=\"picture 4\">",
"      Iliac node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/43/4784\" title=\"picture 5A\">",
"      Dividing left round ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/12/8384\" title=\"picture 5B\">",
"      Left round ligament opened",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/47/10996\" title=\"picture 5C\">",
"      Anatomy left pelvic vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/34/7714\" title=\"picture 6A\">",
"      Pelvic lymphadenectomy1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44785\" title=\"picture 6B\">",
"      Pelvic lymphadenectomy2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/54/40801\" title=\"picture 6C\">",
"      Pelvic lymphadenectomy3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/55/35697\" title=\"picture 6D\">",
"      Pelvic lymphadenectomy4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/14/4323\" title=\"picture 6E\">",
"      Pelvic lymphadenectomy5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/20/36161\" title=\"picture 7A\">",
"      Pelvic lymphadenectomy6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/11/19633\" title=\"picture 7B\">",
"      Pelvic lymphadenectomy7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/40/17024\" title=\"picture 7C\">",
"      Pelvic lymphadenectomy8",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=related_link\">",
"      Cellulitis following pelvic lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4456="Overview of acute pulmonary embolism";
var content_f4_22_4456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of acute pulmonary embolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4456/contributors\">",
"     B Taylor Thompson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Charles A Hales, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4456/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/22/4456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pulmonary embolism (PE) is a common and often fatal disease. Mortality can be reduced by prompt diagnosis and therapy. Unfortunately, the clinical presentation of PE is variable and nonspecific, making accurate diagnosis difficult.",
"   </p>",
"   <p>",
"    The incidence, natural history, pathophysiology, risk factors, symptoms, signs, and outcomes of acute PE are reviewed here. The diagnosis and treatment of acute PE are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PE refers to obstruction of the pulmonary artery or one of its branches by material (eg, thrombus, tumor, air, or fat) that originated elsewhere in the body. This topic review focuses on PE due to thrombus. Air emboli and fat emboli are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PE can be classified as acute or chronic. Patients with acute PE typically develop symptoms and signs immediately after obstruction of pulmonary vessels. In contrast, patients with chronic PE tend to develop slowly progressive dyspnea over a period of years due to pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10503?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute PE can be further classified as massive or submassive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive PE causes hypotension, defined as a systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of &ge;40 mmHg from baseline for a period &gt;15 minutes. It should be suspected anytime there is hypotension accompanied by an elevated central venous pressure (or neck vein distension), which is not otherwise explained by acute myocardial infarction, tension pneumothorax, pericardial tamponade, or a new arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. It is a catastrophic entity that frequently results in acute right ventricular failure and death. When death occurs, it is often within one to two hours of the event, although patients remain at risk for 24 to 72 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. The PE is frequently undiscovered until autopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All acute PE not meeting the definition of massive PE are considered submassive PE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Saddle PE is a PE that lodges at the bifurcation of the main pulmonary artery into the right and left pulmonary arteries. In a retrospective study of 546 consecutive patients with PE, 14 patients (2.6 percent) had saddle PE, only two of whom had hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/7\">",
"     7",
"    </a>",
"    ]. In a similar retrospective study of 680 patients with PE, 37 patients (5.4 percent) had saddle PE, among whom transient hypotension occurred in 14 percent and persistent shock occurred in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, saddle PE are usually submassive and appear to have a similar response to therapy as other types of PE, with a mortality rate of 5.4 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26146960\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of more than 42 million deaths that occurred over a 20 year duration, almost 600,000 patients (approximately 1.5 percent) had been diagnosed with PE, with PE being the presumed cause of death in 200,000 of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/9\">",
"     9",
"    </a>",
"    ]. These are certainly underestimates of the true incidence of PE, since more than half of all PE are probably undiagnosed. Estimates of the incidence of PE have been affected by the introduction of computed tomographic pulmonary angiography (CT-PA) into routine clinical practice, with the estimated incidence increasing from 62.1 to 112.3 cases per 100,000 following the introduction of CT-PA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated PE is associated with a mortality rate of approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/9,12-14\">",
"     9,12-14",
"    </a>",
"    ]. Recurrent embolism is the most common cause of death. The rate of morbidity among untreated survivors is unknown, but appears to be high. Outcomes following treatment are described below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of a patient with an acute PE, certain factors can be detected or measured that may suggest that the patient is at increased risk for mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Right ventricular (RV) dysfunction",
"      </strong>",
"      &ndash; RV dysfunction due to PE predicts increased PE-related mortality if normotensive and hypotensive patients are considered together [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]. This was illustrated by a meta-analysis of seven studies (3395 normotensive or hypotensive patients with PE), which found that RV dysfunction was associated with a twofold increase in PE-related mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The ability of RV dysfunction to predict mortality in patients who do not have hypotension is uncertain because there are contradicting data. In the meta-analysis discussed above, analysis of only normotensive patients found that RV dysfunction correlated poorly with PE-related hospital mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast, another meta-analysis found that RV dysfunction was associated with a two- to threefold increase in mortality in hemodynamically stable patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/16\">",
"       16",
"      </a>",
"      ]. The different outcomes may be due, in part, to the way that RV function was determined. The first meta-analysis assessed RV function echocardiographically, whereas the second assessed RV function via echocardiography or computed tomography.",
"      <br/>",
"      <br/>",
"      RV dysfunction may also predict recurrent PE or DVT. In a prospective cohort study, 301 patients who had experienced their first PE were categorized as having no RV dysfunction, RV dysfunction with regression (ie, present at admission but not at discharge), or persistent RV dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/17\">",
"       17",
"      </a>",
"      ]. During a mean follow up of three years, patients with persistent RV dysfunction were more likely to have a recurrent PE, recurrent DVT, or PE-related death, compared to patients with no RV dysfunction or RV dysfunction with regression.",
"     </li>",
"     <li>",
"      <strong>",
"       Brain natriuretic peptides",
"      </strong>",
"      &ndash; An elevated brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts RV dysfunction and mortality, according to three meta-analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. As an example, a meta-analysis of 16 studies found that short-term mortality was increased six times among patients with a BNP &gt;100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      and 16 times among patients with an NT-proBNP &gt;600",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      BNP and NT-proBNP may predict other adverse outcomes. In an observational study of 73 consecutive patients diagnosed with acute PE, serum BNP levels &gt;90",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (drawn within four hours of presentation) were associated with cardiopulmonary resuscitation, mechanical ventilation, vasopressor therapy, thrombolysis, and embolectomy, as well as death [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/21\">",
"       21",
"      </a>",
"      ]. Serum BNP levels &lt;50",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      identified 95 percent of patients with a benign clinical course.",
"      <br/>",
"      <br/>",
"      BNP and NT-proBNP are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Deep vein thrombosis",
"      </strong>",
"      &ndash; Patients who present with an acute PE and are subsequently found to have a coexisting deep vein thrombosis (DVT) are at increased risk for mortality. This was illustrated by a prospective cohort study of 707 patients with acute PE that found that DVT was associated with both increased all-cause mortality (adjusted HR 2.05, 95% CI 1.24-3.38) and increased PE-specific mortality (adjusted HR 4.25, 95% CI 1.61-11.25) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       RV thrombus",
"      </strong>",
"      &ndash; Patients with PE and a right ventricular (RV) thrombus have a higher 14-day mortality (21 versus 11 percent) and three-month mortality (29 versus 16 percent) than patients without an RV thrombus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Serum troponins",
"      </strong>",
"      &ndash; Elevated serum troponin levels are associated with an increased risk of death in patients with PE [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. This is illustrated by a meta-analysis of 20 observational studies (1985 patients), which found that patients with an elevated troponin I or troponin T level had an increased risk of short-term mortality (OR 5.24, 95% CI 3.28-8.38) or death due to PE (OR 9.44, 95% CI 4.14-21.49) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Troponin levels can be combined with NT-proBNP levels to derive more precise prognostic information. In a prospective study of 100 consecutive patients with PE, a troponin T level &gt;0.07",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      plus an NT-proBNP level &ge;600",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      was associated with a higher 40-day mortality than a troponin T level &gt;0.07",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      plus an NT-proBNP level &lt;600",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      (33 versus zero percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The serum troponins are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"       \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hyponatremia",
"      </strong>",
"      &ndash; Hyponatremia at the time of presentation is associated with increased mortality and hospital readmission. This was demonstrated by a retrospective cohort study of 13,728 patients who were discharged over a two year period with a primary diagnosis of PE [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/28\">",
"       28",
"      </a>",
"      ]. Compared to a sodium level &gt;135",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      30-day mortality was increased among patients who presented with a sodium level of 130 to 135",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (odds ratio 1.53, 95% CI 1.33-1.76) or a sodium level of &lt;130",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (odds ratio 3.26, 95% CI 2.48-4.29). The absolute 30-day mortality rates among patients who presented with sodium levels of &gt;135, 130 to 135, and &lt;130",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      were 8, 13.6, and 28.5 percent, respectively. Hospital readmission within 30 days was also more common among patients who presented with hyponatremia.",
"     </li>",
"     <li>",
"      <strong>",
"       Prognostic models",
"      </strong>",
"      &ndash; Several prognostic models have been derived and validated in patients with acute PE [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. The Pulmonary Embolism Severity Index (PESI) may be the most well known.",
"      <br/>",
"      <br/>",
"      The original PESI obtains a total point score by adding the patient&rsquo;s age to the points assigned to each of ten variables: male sex (+10 points), history of cancer (+30 points), heart failure (+10 points), chronic lung disease (+10 points), pulse &ge;110 bpm (+20 points), systolic blood pressure &lt;100 mmHg (+30 points), respiratory rate &ge;30 breaths per minute (+20 points), temperature &lt;36 degrees C (+20 points), altered mental status (+60 points), and arterial oxygen saturation &lt;90 percent (+20 points) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/29\">",
"       29",
"      </a>",
"      ]. The total point score categorizes the patient according to his or her risk for mortality: risk class I (&lt;66 points), risk class II (66 to 85 points), risk class III (86-105 points), risk class IV (106-125 points), and risk class V (&gt;125 points). The major limitation of the PESI is that it is difficult to apply in a busy clinical setting because so many variables must be considered, each with its own weight.",
"      <br/>",
"      <br/>",
"      To address this limitation, a simplified version of the PESI was developed. The simplified PESI assigns one point for each of the following variables: age &gt;80 years, a history of cancer, chronic cardiopulmonary disease, a heart rate &ge;110 beats per minute, a systolic blood pressure &lt;100 mmHg, and an arterial oxyhemoglobin saturation &lt;90 percent. A total point score of zero indicates a low risk for mortality, while a score of one or more indicates a high risk [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The simplified PESI appears to have a prognostic accuracy that is similar to the original PESI. In a cohort of 995 patients, those classified by the simplified PESI as low risk had a 30-day mortality rate of 1 percent, whereas patients classified as high risk had a 30-day mortality rate of 10.9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/32\">",
"       32",
"      </a>",
"      ]. In comparison, patients classified by the original PESI as low risk had a 30-day mortality rate of 2.5 percent, whereas patients classified as high risk had a 30-day mortality rate of 10.9 percent. Prospective validation of the simplified PESI is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most PE arise from thrombi in the deep venous system of the lower extremities. However, they may also originate in the right heart or the pelvic, renal, or upper extremity veins.",
"   </p>",
"   <p>",
"    Iliofemoral veins are the source of most clinically recognized PE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. It is estimated that 50 to 80 percent of iliac, femoral, and popliteal vein thrombi (proximal vein thrombi) originate below the popliteal vein (calf vein thrombi) and propagate proximally. The remainder arise within the proximal veins. Fortunately, most calf vein thrombi resolve spontaneously and only 20 to 30 percent extend into the proximal veins if untreated. Most lower extremity thrombi develop at sites of decreased flow, such as valve cusps or bifurcations.",
"   </p>",
"   <p>",
"    After traveling to the lung, large thrombi may lodge at the bifurcation of the main pulmonary artery or the lobar branches and cause hemodynamic compromise. Smaller thrombi continue traveling distally and are more likely to produce pleuritic chest pain, presumably by initiating an inflammatory response adjacent to the parietal pleura. Only about 10 percent of emboli cause pulmonary infarction, usually in patients with preexisting cardiopulmonary disease. Most pulmonary emboli are multiple, with the lower lobes being involved in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired gas exchange due to PE cannot be explained solely on the basis of mechanical obstruction of the vascular bed and alterations in the ventilation to perfusion ratio. Gas exchange abnormalities are also related to the release of inflammatory mediators, resulting in surfactant dysfunction, atelectasis, and functional intrapulmonary shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypotension is due to diminished cardiac output (CO), which results from increased pulmonary vascular resistance (PVR) impeding right ventricular outflow and reducing left ventricular preload. PVR is increased from physical obstruction of the vascular bed with thrombus and vasoconstriction, the latter due to the effects of inflammatory mediators and hypoxia. In normal subjects experiencing pulmonary thromboembolism, the correlation of pulmonary artery pressure to thrombus size is limited by the variable contribution of vasoconstriction among and perhaps within subjects. However, when obstruction of the vascular bed approaches 75 percent, the right ventricle must generate a systolic pressure in excess of 50 mmHg and a mean pulmonary artery pressure approximating 40 mmHg to preserve pulmonary perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/39\">",
"     39",
"    </a>",
"    ]. The normal right ventricle is unable to accomplish this and may eventually fail.",
"   </p>",
"   <p>",
"    Patients with underlying cardiopulmonary disease experience more substantial deterioration in CO than normal individuals. In addition, right ventricular failure following PE is more common in patients who have coexisting coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PE is a common complication of deep vein thrombosis (DVT), occurring in more than 50 percent of cases with phlebographically confirmed DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/40\">",
"     40",
"    </a>",
"    ]. This suggests that factors that promote the development of DVT also increase the risk for PE. Such risk factors are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While much of the data related to risk factors are from patients with DVT, a few studies have looked specifically at patients with acute PE. Most patients with acute PE have an identifiable risk factor at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"     41",
"    </a>",
"    ]. Risk factors include immobilization, surgery within the last three months, stroke, paresis, paralysis, central venous instrumentation within the last three months, malignancy, chronic heart disease, autoimmune diseases, and a history of venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. Additional risk factors identified in women include obesity (BMI &ge;29",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    heavy cigarette smoking (&gt;25 cigarettes per day), and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SYMPTOMS / SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific symptoms and signs are not helpful diagnostically because their frequency is similar among patients with and without PE. In the Prospective Investigation of Pulmonary Embolism Diagnosis II (PIOPED II), the following frequencies of symptoms and signs were noted among patients with PE who did not have preexisting cardiopulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41,48\">",
"     41,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common symptoms were dyspnea at rest or with exertion (73 percent), pleuritic pain (44 percent), cough (34 percent), &gt;2-pillow orthopnea (28 percent), calf or thigh pain (44 percent), calf or thigh swelling (41 percent), and wheezing (21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"       41",
"      </a>",
"      ]. The onset of dyspnea was usually within seconds (46 percent) or minutes (26 percent).",
"     </li>",
"     <li>",
"      The most common signs were tachypnea (54 percent), tachycardia (24 percent), rales (18 percent), decreased breath sounds (17 percent), an accentuated pulmonic component of the second heart sound (15 percent), and jugular venous distension (14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Circulatory collapse was uncommon (8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"       41",
"      </a>",
"      ]. Among such patients, dyspnea was present in 82 percent and either dyspnea or tachypnea was present in 91 percent. Massive PE may be accompanied by acute right ventricular failure, manifested by increased jugular venous pressure, a right-sided S3, and a parasternal lift.",
"     </li>",
"     <li>",
"      Symptoms or signs of lower extremity deep venous thrombosis (DVT) were common (47 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"       41",
"      </a>",
"      ]. They included edema, erythema, tenderness, or a palpable cord in the calf or thigh.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to realize that pulmonary embolism is frequently asymptomatic. This was demonstrated by a systematic review of 28 studies that found that among the 5233 patients who had a deep vein thrombosis, 1665 (32 percent) had asymptomatic PE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of PE are highly variable, nonspecific, and common among patients with and without PE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/1,50\">",
"     1,50",
"    </a>",
"    ]. Thus additional testing is needed to confirm or exclude the diagnosis of PE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of acute PE is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation is the mainstay of therapy for acute PE. Other treatment strategies include thrombolysis, inferior vena caval filters, and embolectomy. Treatment of acute PE is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective anticoagulant therapy decreases the mortality rate from approximately 30 percent to 2 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/9,12-14\">",
"     9,12-14",
"    </a>",
"    ]. However, morbidity is common among survivors.",
"   </p>",
"   <p>",
"    Pulmonary hypertension is a consequence of acute PE, as illustrated by an observational study that included 144 patients with confirmed PE who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/51\">",
"     51",
"    </a>",
"    ]. Approximately 50 percent of the patients had persistent or worsened elevation of their right ventricular systolic pressure six months after their acute PE, suggesting pulmonary hypertension. This was frequently accompanied by dyspnea at rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise intolerance.",
"   </p>",
"   <p>",
"    The likelihood of morbidity and mortality following treatment may be influenced by whether the acute PE occurred in the absence of risk factors or predisposing illnesses (ie, unprovoked PE). An observational study that followed 308 consecutive patients who were being treated for an acute PE (median duration of follow-up was 3.3 years) found that patients with unprovoked PE were more likely to develop recurrent PE, chronic thromboembolic pulmonary hypertension, malignancy, or cardiovascular events than patients with risk factors for PE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/52\">",
"     52",
"    </a>",
"    ]. In contrast, patients with risk factors for PE had a higher risk for mortality.",
"   </p>",
"   <p>",
"    An association between acute PE and a subsequent increased risk for all-cause mortality has been demonstrated. In a retrospective cohort study of 1023 patients with confirmed PE, the 5-year mortality rate was 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/53\">",
"     53",
"    </a>",
"    ]. Only five percent of the deaths were due to PE; 64 percent were due to non-cardiovascular causes (eg, malignancy, sepsis) and 31 percent were due to cardiovascular causes other than PE (eg, myocardial infarction, heart failure, and stroke). One year follow-up of the PIOPED cohort revealed similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4456/abstract/12\">",
"     12",
"    </a>",
"    ]. These studies support the conclusion that deaths one to five years following pulmonary emboli are largely determined by the predisposing comorbidities rather than pulmonary emboli per se.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"       \"Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute pulmonary embolism (PE) is a common and often fatal disease. It can be classified as massive or submassive. Massive acute PE causes hypotension, defined as a systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of &ge;40 mmHg from baseline for &gt;15 minutes. All acute PE not meeting the definition of massive PE are considered submassive PE. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute PE is associated with a mortality rate of approximately 30 percent without treatment, primarily due to recurrent embolism. However, accurate diagnosis followed by effective anticoagulant therapy decreases the mortality rate to 2 to 8 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Natural history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that promote the development of deep vein thrombosis also increase the risk for PE. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"       \"Overview of the causes of venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common symptoms of acute PE are dyspnea at rest or with exertion, pleuritic pain, cough, &gt;2-pillow orthopnea, calf or thigh pain or swelling, and wheezing. The most common signs are tachypnea, tachycardia, rales, decreased breath sounds, an accentuated pulmonic component of the second heart sound, and jugular venous distension. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Symptoms / Signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and signs of PE are highly variable, nonspecific, and common among patients with and without PE. Thus, additional testing is needed to confirm or exclude the diagnosis of PE. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticoagulation is the mainstay of therapy for acute PE. Other treatment strategies include thrombolysis, inferior vena caval filters, and embolectomy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/1\">",
"      Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/2\">",
"      Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/3\">",
"      COON WW, WILLIS PW. Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment. Am J Cardiol 1959; 4:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/4\">",
"      Soloff LA, Rodman T. Acute pulmonary embolism. II. Clinical. Am Heart J 1967; 74:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/5\">",
"      Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 1985; 72:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/6\">",
"      Goldhaber SZ, Hennekens CH, Evans DA, et al. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982; 73:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/7\">",
"      Ryu JH, Pellikka PA, Froehling DA, et al. Saddle pulmonary embolism diagnosed by CT angiography: frequency, clinical features and outcome. Respir Med 2007; 101:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/8\">",
"      Sardi A, Gluskin J, Guttentag A, et al. Saddle pulmonary embolism: is it as bad as it looks? A community hospital experience. Crit Care Med 2011; 39:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/9\">",
"      Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/10\">",
"      Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011; 171:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/11\">",
"      Kr&ouml;ger K, K&uuml;pper-Nybelen J, Moerchel C, et al. Prevalence and economic burden of pulmonary embolism in Germany. Vasc Med 2012; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/12\">",
"      Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/13\">",
"      Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/14\">",
"      Nijkeuter M, S&ouml;hne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest 2007; 131:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/15\">",
"      ten Wolde M, S&ouml;hne M, Quak E, et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/16\">",
"      Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/17\">",
"      Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006; 166:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/18\">",
"      Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med 2008; 34:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/19\">",
"      Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/20\">",
"      Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/21\">",
"      Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/22\">",
"      Jim&eacute;nez D, Aujesky D, D&iacute;az G, et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010; 181:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/23\">",
"      Torbicki A, Gali&eacute; N, Covezzoli A, et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003; 41:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/24\">",
"      Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/25\">",
"      Jim&eacute;nez D, Uresandi F, Otero R, et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/26\">",
"      Janata KM, Leitner JM, Holzer-Richling N, et al. Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J 2009; 34:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/27\">",
"      Kostrubiec M, Pruszczyk P, Bochowicz A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/28\">",
"      Scherz N, Labar&egrave;re J, M&eacute;an M, et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med 2010; 182:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/29\">",
"      Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/30\">",
"      Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/31\">",
"      Uresandi F, Otero R, Cayuela A, et al. [A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism]. Arch Bronconeumol 2007; 43:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/32\">",
"      Jim&eacute;nez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/33\">",
"      Kistner RL, Ball JJ, Nordyke RA, Freeman GC. Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities. Am J Surg 1972; 124:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/34\">",
"      Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/35\">",
"      Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/36\">",
"      van Langevelde K, Sr&aacute;mek A, Vincken PW, et al. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica 2013; 98:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/37\">",
"      Moser KM. Venous thromboembolism. Am Rev Respir Dis 1990; 141:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/38\">",
"      Nakos G, Kitsiouli EI, Lekka ME. Bronchoalveolar lavage alterations in pulmonary embolism. Am J Respir Crit Care Med 1998; 158:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/39\">",
"      Benotti JR, Dalen JE. The natural history of pulmonary embolism. Clin Chest Med 1984; 5:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/40\">",
"      Girard P, Decousus M, Laporte S, et al. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med 2001; 164:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/41\">",
"      Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/42\">",
"      Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990; 263:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/43\">",
"      Darze ES, Latado AL, Guimar&atilde;es AG, et al. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005; 128:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/44\">",
"      Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/45\">",
"      Pulido T, Aranda A, Zevallos MA, et al. Pulmonary embolism as a cause of death in patients with heart disease: an autopsy study. Chest 2006; 129:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/46\">",
"      Z&ouml;ller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/47\">",
"      Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/48\">",
"      Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/49\">",
"      Stein PD, Matta F, Musani MH, Diaczok B. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 2010; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/50\">",
"      Le Gal G, Testuz A, Righini M, et al. Reproduction of chest pain by palpation: diagnostic accuracy in suspected pulmonary embolism. BMJ 2005; 330:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/51\">",
"      Kline JA, Steuerwald MT, Marchick MR, et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009; 136:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/52\">",
"      Klok FA, Zondag W, van Kralingen KW, et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 2010; 181:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4456/abstract/53\">",
"      Ng AC, Chung T, Yong AS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011; 4:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8253 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4456=[""].join("\n");
var outline_f4_22_4456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26146960\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SYMPTOMS / SIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10503?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=related_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4457="Cervical insufficiency";
var content_f4_22_4457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical insufficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4457/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/22/4457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, the term &lsquo;cervical insufficiency&rsquo; was used to describe a disorder in which painless cervical dilation led to recurrent second trimester pregnancy",
"    <span class=\"nowrap\">",
"     losses/births",
"    </span>",
"    of otherwise normal pregnancies. Structural weakness of cervical tissue was thought to cause or contribute to these adverse outcomes. The diagnosis has also been applied to women with one or two such",
"    <span class=\"nowrap\">",
"     losses/deliveries",
"    </span>",
"    or at risk for such a",
"    <span class=\"nowrap\">",
"     loss/delivery.",
"    </span>",
"   </p>",
"   <p>",
"    Although",
"    structural cervical weakness is the source of some preterm",
"    <span class=\"nowrap\">",
"     losses/births,",
"    </span>",
"    most are caused by other disorders, such as decidual",
"    <span class=\"nowrap\">",
"     inflammation/infection,",
"    </span>",
"    hemorrhage, or uterine overdistension. These disorders can initiate biochemical changes in the cervix that lead to premature cervical shortening and, often, pregnancy loss or preterm birth. These disorders usually do not recur in successive pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7413947\">",
"    <span class=\"h2\">",
"     Past obstetrical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical factors suggestive of cervical insufficiency include a history of second trimester pregnancy",
"    <span class=\"nowrap\">",
"     losses/deliveries,",
"    </span>",
"    especially in the setting of short labors or progressively earlier deliveries in successive pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7413900\">",
"    <span class=\"h2\">",
"     Cervical risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for cervical insufficiency can be congenital or acquired; acquired factors are more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7413547\">",
"    <span class=\"h3\">",
"     Congenital factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Collagen abnormalities",
"      </strong>",
"      &mdash; Alterations in the regulation of type I collagen expression may influence cervical ripening [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/1,2\">",
"       1,2",
"      </a>",
"      ], and genetic disorders affecting collagen (eg, Ehlers-Danlos syndrome) have been associated with increased risk of preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/3\">",
"       3",
"      </a>",
"      ]. This may explain familial aggregation of cervical insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/4\">",
"       4",
"      </a>",
"      ]. As an example, in one study, 34 of 125 (27 percent) women with cervical insufficiency had a first degree relative with the same diagnosis, but none of the 165 unaffected women had a family history of cervical insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Uterine anomalies",
"      </strong>",
"      &mdash; Congenital structural uterine abnormalities may involve the cervix and be associated with cervical insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/5\">",
"       5",
"      </a>",
"      ]. The risk of second trimester preterm birth is increased with uterine anomalies, including canalization defects (eg, septate uterus), unification defects (eg, bicornuate uterus), and even arcuate uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diethylstilbestrol (DES) exposure",
"      </strong>",
"      &mdash; In utero DES exposure has been linked to subsequent cervical insufficiency when the DES daughter became pregnant [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/7\">",
"       7",
"      </a>",
"      ]. Pregnancy in DES daughters is now uncommon, as almost all of these women are over 40 years old. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=see_link\">",
"       \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Biologic variation",
"      </strong>",
"      &mdash; The length of the cervix during the second trimester in an obstetric population is distributed in a bell-shaped curve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link&amp;anchor=H7011713#H7011713\">",
"       \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\", section on 'Short cervical length'",
"      </a>",
"      .) The wide range in normal cervical length (the 10",
"      <sup>",
"       th",
"      </sup>",
"      and 90",
"      <sup>",
"       th",
"      </sup>",
"      percentiles are 25 and 45 mm, respectively) during this period is due, in part, to biologic variation, but may also result from premature cervical effacement. Although a short cervix is predictive of preterm birth, it is not diagnostic of cervical insufficiency and many women who have a congenitally short cervix deliver at term.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7413555\">",
"    <span class=\"h3\">",
"     Acquired factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Obstetric trauma",
"      </strong>",
"      &mdash; A cervical laceration may occur during labor or in the process of delivery, including spontaneous, forceps, vacuum, or cesarean birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/8\">",
"       8",
"      </a>",
"      ]. This might weaken the cervix, and contribute to cervical insufficiency.",
"     </li>",
"     <li>",
"      <strong>",
"       Mechanical dilation",
"      </strong>",
"      &mdash; Cervical insufficiency has also been attributed to rapid mechanical dilation of the cervix during gynecologic procedures (eg, dilation and curettage [D&amp;C], dilation and evacuation [D&amp;E], pregnancy termination, hysteroscopy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. In women with a short cervical length and no prior preterm birth, prior cervical mechanical dilatation is one of the most common associated risk factors. In a meta-analysis, an increasing number of voluntary pregnancy terminations was associated with an increasing risk of spontaneous preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/10\">",
"       10",
"      </a>",
"      ]. Trauma to the cervix during gynecologic procedures may be prevented if the cervix is gradually ripened with laminaria or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , or if pregnancy termination is performed medically [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H33#H33\">",
"       \"Overview of pregnancy termination\", section on 'Future pregnancies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment of cervical intraepithelial neoplasia",
"      </strong>",
"      &mdash; Treatment of cervical intraepithelial neoplasia has been associated with an increased risk of subsequent pregnancy",
"      <span class=\"nowrap\">",
"       loss/preterm",
"      </span>",
"      birth. This topic is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16200?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7413977\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical insufficiency may be asymptomatic or may present with mild symptoms such as pelvic pressure, premenstrual-like cramping or backache, and increased vaginal discharge. These symptoms have usually been present over several days or weeks, typically beginning around 14 to 20 weeks of gestation. A slight change in the color (from clear, white, or light yellow to pink, tan, or spotting) and consistency (thinner) of vaginal discharge is also consistent with cervical ripening from any cause.",
"   </p>",
"   <p>",
"    Contractions are absent or mild.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263423507\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical examination may reveal a soft somewhat effaced cervix, with minimal, if any, dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/13\">",
"     13",
"    </a>",
"    ]. Application of suprapubic or fundal pressure, or Valsalva, as a provocative maneuver rarely reveals membranes in the endocervical canal or vagina; this is always abnormal. Tocodynamometry usually reveals no or infrequent contractions at irregular intervals.",
"   </p>",
"   <p>",
"    Late clinical presentation is characterized by advanced dilation and effacement (eg, &ge;4 cm dilated and &ge;80 percent effaced), spotting, unprovoked grossly prolapsed membranes or ruptured membranes, or contractions that seem inadequate to explain the advanced effacement and dilation.",
"   </p>",
"   <p>",
"    The presence of infection, bleeding from placental causes (eg, previa or abruption), or multiple gestation, which are associated with preterm birth independent of cervical insufficiency, suggests an alternative diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263423514\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before 28 weeks of gestation, cervical length by transvaginal ultrasound below the 10th percentile (25 mm) is consistently associated with an increased risk of spontaneous preterm birth. Other sonographic features suggestive of increased risk of preterm birth include separation of the membranes and debris (sludge) in the amniotic fluid. These findings are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263428260\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory abnormalities characteristically associated with uncomplicated cervical insufficiency.",
"   </p>",
"   <p>",
"    In some cases, cervical insufficiency is caused by, or leads to, subclinical intraamniotic infection, which can be diagnosed by examination of amniotic fluid from amniocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link&amp;anchor=H7#H7\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervico-vaginal fetal fibronectin may be positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15848061\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cervical insufficiency is either based on historic factors or, preferably, by a combination of historic factors and transvaginal ultrasound (TVU) measurement of cervical length.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using historic factors alone, cervical insufficiency is defined as painless cervical dilatation leading to recurrent second trimester pregnancy",
"      <span class=\"nowrap\">",
"       losses/births.",
"       <strong>",
"       </strong>",
"      </span>",
"      This definition precludes diagnosis of cervical insufficiency until at least two pregnancy",
"      <span class=\"nowrap\">",
"       losses/births",
"      </span>",
"      before 28 weeks of gestation have occurred.",
"     </li>",
"     <li>",
"      A preferable definition allows the diagnosis of cervical insufficiency to be made in primigravidas or in multigravidas without multiple prior pregnancy losses. Using this definition, cervical insufficiency is defined by TVU cervical length &lt;25 mm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced cervical changes on physical examination before 24 weeks of gestation in women with either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or more prior pregnancy losses or preterm births at 14 to 36 weeks,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Other significant risk factors for cervical insufficiency (see",
"      <a class=\"local\" href=\"#H7413900\">",
"       'Cervical risk factors'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of cervical insufficiency is usually limited to singleton gestations because the pathogenesis of delivery at 14 to 28 weeks in multiple gestations is usually unrelated to a weakened cervix. In addition, preterm labor, infection, abruptio placenta, and bleeding placenta previa should be excluded, as these disorders could account for biochemically mediated cervical ripening leading to second trimester pregnancy loss or preterm delivery independent of",
"    <span class=\"nowrap\">",
"     structural/anatomic",
"    </span>",
"    cervical weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/14\">",
"     14",
"    </a>",
"    ]. Although the rate of decrease in cervical length over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/15\">",
"     15",
"    </a>",
"    ] and shortening before 20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] are associated with an increased risk of early preterm birth, these findings do not absolutely distinguish cervical insufficiency from other causes of preterm delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263427240\">",
"    <span class=\"h2\">",
"     Can cervical insufficiency be diagnosed before pregnancy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cervical insufficiency cannot be made or excluded outside of pregnancy by any test. Evaluation of cervical function with dilators, balloons, or hysteroscopy is not helpful. Ultrasound, magnetic resonance imaging, or hysterosalpingography may reveal a uterine anomaly, which is a risk factor for cervical insufficiency, but is not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25211294\">",
"    <span class=\"h2\">",
"     Women with prior pregnancy losses or preterm births",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14004814\">",
"    <span class=\"h3\">",
"     Candidates for history-indicated cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of recurrent second trimester",
"    <span class=\"nowrap\">",
"     losses/births",
"    </span>",
"    are primarily, and perhaps exclusively, caused by congenital or acquired structural weakness of the cervix, and can be treated effectively with support by a &ldquo;history-indicated&rdquo; cerclage. Anatomical, biochemical, and clinical evidence from observational studies and randomized trials consistently support this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest history-indicated cerclage at 12 to 14 weeks for women who meet",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef71782 \" href=\"UTD.htm?0/57/924\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two or more consecutive prior second trimester pregnancy losses or three or more early (&lt;34 weeks) preterm births.",
"     </li>",
"     <li>",
"      Risk factors for cervical insufficiency. As discussed above, these risk factors include a history of cervical trauma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      short labors or progressively earlier deliveries in successive pregnancies (see",
"      <a class=\"local\" href=\"#H7413947\">",
"       'Past obstetrical history'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7413900\">",
"       'Cervical risk factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Other causes of preterm birth (eg, infection, placental bleeding, multiple gestation) have been excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique for cerclage is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link\">",
"     \"Transvaginal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also treat these women with 17-alpha-hydroxyprogesterone caproate weekly from 16 to 36 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Although randomized trials support the benefit of history-indicated cerclage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/19\">",
"     19",
"    </a>",
"    ] and the benefit of progesterone supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/23-25\">",
"     23-25",
"    </a>",
"    ] in this population, no trials have evaluated the efficacy of combination therapy (both history-indicated cerclage and 17 alpha hydroxy-progesterone caproate).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14004837\">",
"    <span class=\"h3\">",
"     Candidates for ultrasound surveillance and possible ultrasound indicated cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of women with suspected cervical insufficiency do not meet the above criteria for history-indicated cerclage. For these women, we usually initiate TVU cervical length screening (",
"    <a class=\"graphic graphic_table graphicRef70801 \" href=\"UTD.htm?19/33/19995\">",
"     table 2",
"    </a>",
"    ), administer 17-alpha-hydroxyprogesterone caproate prophylaxis, and apply a cerclage if cervical length decreases to &lt;25 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/26\">",
"     26",
"    </a>",
"    ]. The rationale for this approach is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with a short cervix on transvaginal ultrasound examination are at increased risk of spontaneous preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In women with a history of spontaneous preterm birth, a systematic review of controlled studies showed that measurement of cervical length in the second trimester, especially before 24 weeks, predicted the risk of recurrent preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/27\">",
"       27",
"      </a>",
"      ]. The use of a TVU cervical length &lt;25 mm at &lt;24 weeks to predict preterm birth at &lt;35 weeks yielded sensitivity of 65.4 percent, specificity of 75.5 percent, positive predictive value of 33.0 percent, and negative predictive value of 92.0 percent. The shorter the cervical length, the higher the positive likelihood ratio for spontaneous preterm birth &lt;35 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In randomized trials, progesterone prophylaxis with 17 alpha hydroxy-progesterone caproate starting at 16 to 20 weeks in women with a history of spontaneous preterm birth and continuing until 36 weeks reduced the risk of recurrent preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Placement of cerclage upon identification of a short cervix (&ldquo;ultrasound-indicated cerclage&rdquo;) is effective in reducing preterm birth [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/28\">",
"       28",
"      </a>",
"      ], results in pregnancy outcomes comparable to those with history-indicated cerclage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/29\">",
"       29",
"      </a>",
"      ], and avoids cerclage in about 60 percent of patients with a suggestive history [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/29\">",
"       29",
"      </a>",
"      ]. The benefit of ultrasound-indicated cerclage may derive from bolstering cervical strength [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/30\">",
"       30",
"      </a>",
"      ], preventing membranes from being exposed, and retention of the mucus plug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a meta-analysis of randomized trials of women with singleton gestation and prior spontaneous preterm birth and short cervical length &lt;25 mm before 24 weeks, treatment with ultrasound-indicated cerclage significantly lowered total neonatal morbidity and mortality (15.6 versus 24.8 percent without cerclage; RR 0.64, 95% CI 0.45-0.91), presumably because cerclage significantly reduced the frequency of preterm birth (delivery &lt;35 weeks RR 0.70, 95% CI 0.55-0.89; 28.4 percent versus 41.3 percent in women without cerclage) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another meta-analysis of randomized trials of women with singleton gestations and prior preterm birth managed either by (1) cervical length screening with cerclage for short cervical length or (2) history-indicated cerclage, patients with ultrasound-indicated versus history-indicated cerclage had similar rates of preterm birth before 37 weeks (31 versus 32 percent, RR 0.97, 95% CI 0.73-1.29), preterm birth before 34 weeks (17 versus 23 percent, RR 0.76, 95% CI 0.48-1.20), and perinatal mortality (5 versus 3 percent, RR 1.77, 95% CI 0.58-5.35), and only 42 percent developed a short cervical length and received cerclage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We usually initiate cervical length screening at 14 weeks, but may screen as early as 12 weeks in women with early second trimester losses, recurrent second trimester losses, or prior large cold knife conization (",
"    <a class=\"graphic graphic_table graphicRef70801 \" href=\"UTD.htm?19/33/19995\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/31\">",
"     31",
"    </a>",
"    ]. In women with prior preterm birth at 28 to 36 weeks, we initiate screening at 16 weeks. Ultrasound examination is generally repeated every two weeks until 24 weeks as long as the cervical length is &ge;30 mm, and increased to weekly if cervical length is 25 to 29 mm, with the expectation that preterm cervical changes will precede overt preterm labor or membrane rupture symptoms by three to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/32\">",
"     32",
"    </a>",
"    ]. Transvaginal ultrasound screening is usually discontinued at 24 weeks of gestation, as cerclage is not usually performed after this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We continue intramuscular progesterone supplementation until 36 weeks, whether or not a cerclage is placed. Although no studies have reported a statistically significant improvement in pregnancy outcome with combined therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ], these studies are retrospective analyses and underpowered. One post-hoc analysis of data from a randomized trial observed that the rate of early preterm birth trended lower in women who received both 17-alpha-hydroxyprogesterone caproate and ultrasound-indicated cerclage than in those who received either therapy alone (preterm birth &lt;28 weeks: both interventions: 9 percent versus cerclage alone: 17 percent and progesterone alone: 15 percent; preterm birth &lt;32 weeks: both interventions: 17 percent versus cerclage alone: 25 and progesterone alone: 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized controlled trial has directly compared vaginal progesterone, intramuscular 17-alpha-hydroxyprogesterone caproate, and cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix in the mid trimester, singleton gestation, and previous preterm birth. An indirect comparison meta-analysis concluded vaginal progesterone and cerclage were equally efficacious in the prevention of preterm birth in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/36\">",
"     36",
"    </a>",
"    ]. Based on evidence from the direct comparisons in the randomized trials discussed above, we treat women with prior preterm birth with intramuscular 17-alpha-hydroxyprogesterone caproate and then perform cerclage if the cervical length becomes less than 25 mm. (See",
"    <a class=\"local\" href=\"#H25211294\">",
"     'Women with prior pregnancy losses or preterm births'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7414928\">",
"    <span class=\"h2\">",
"     Women with singleton pregnancy, no prior birth, but risk factors for cervical insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of women with risk factors for cervical insufficiency, such as uterine anomaly, prior minor cervical surgery, or pregnancy termination, observed a correlation between risk of preterm birth and short cervical length, but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. A wide range of recurrent preterm birth rates has been reported in these studies, depending on the cervical length threshold used and the gestational age at the time of measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/40\">",
"     40",
"    </a>",
"    ]. No intervention has been evaluated by randomized trials specifically in these populations.",
"   </p>",
"   <p>",
"    We perform a single TVU cervical length measurement at 18 to 24 weeks in women with risk factors for cervical insufficiency and no prior delivery (",
"    <a class=\"graphic graphic_table graphicRef70801 \" href=\"UTD.htm?19/33/19995\">",
"     table 2",
"    </a>",
"    ), and treat those with a short cervix (&le;20 mm) with vaginal progesterone supplementation (",
"    <a class=\"graphic graphic_table graphicRef70801 \" href=\"UTD.htm?19/33/19995\">",
"     table 2",
"    </a>",
"    ). In a meta-analysis of five trials, administration of vaginal progesterone to women with a short cervix reduced the rate of spontaneous preterm birth and composite neonatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/41\">",
"     41",
"    </a>",
"    ], and it appears to be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419366#H14419366\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Short cervix in current pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16200?source=see_link&amp;anchor=H17#H17\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\", section on 'Obstetric management in subsequent pregnancies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient delivers preterm, subsequent pregnancies are managed as described above (see",
"    <a class=\"local\" href=\"#H25211294\">",
"     'Women with prior pregnancy losses or preterm births'",
"    </a>",
"    above). If she delivers at term, we again perform a single cervical length measurement at 18 to 24 weeks and give vaginal progesterone if the cervix is short.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Short cervix at &lt;24 weeks, no prior preterm birth, no risk factors for preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women do not meet our definition for diagnosis of cervical insufficiency (see",
"    <a class=\"local\" href=\"#H15848061\">",
"     'Diagnosis'",
"    </a>",
"    above). The management of their pregnancies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link&amp;anchor=H7012170#H7012170\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\", section on 'Singleton, no prior preterm birth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89361408\">",
"    <span class=\"h2\">",
"     Physical examination reveals a dilated cervix and visible membranes before 24 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, a woman presents before 24 weeks with minimal or no symptoms and physical examination reveals a dilated cervix. Occasionally, such findings follow the identification of a very short cervical length (eg, &lt;5 mm) on TVU. The management of these cases is governed primarily by whether a condition that would likely lead to prompt delivery is present, such as overt infection, ruptured membranes, or significant hemorrhage. In the absence of indications for delivery, the gestational age and degree of cervical dilation are the next considerations. Prior to viability, management is aimed at prolonging the pregnancy; some parents may choose pregnancy termination, especially for preterm premature rupture of membranes (PPROM) or advanced (&gt;4 cm) cervical dilation. After viability, the goal is to both prolong the pregnancy and improve neonatal outcome in the likely event of preterm birth.",
"   </p>",
"   <p>",
"    Data from several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/44-46\">",
"     44-46",
"    </a>",
"    ] suggest that a grossly dilated cervix with visible membranes may be an appropriate criterion for placement of a &ldquo;physical exam-indicated cerclage&rdquo; in some cases. Placement of a physical exam-indicated cerclage when a dilated cervix and visible membranes are detected on digital examination at &lt;24 weeks appeared to prolong pregnancy and improve pregnancy outcome compared to expectant management in both a small trial and retrospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Due to differences in patient populations, actual outcomes varied among these studies. Physical exam-indicated cerclage should only be considered in women with visible bulging membranes in the absence of infection, labor, and vaginal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link\">",
"     \"Transvaginal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women without clinical signs of infection, we offer amniocentesis to check for subclinical infection when the cervix is &ge;2 cm dilated and on a case-by-case basis when there are ultrasound findings suggestive of inflammation: membrane edema, separation of membranes from the decidua, or debris in the amniotic fluid (&ldquo;sludge&rdquo;) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70493 \" href=\"UTD.htm?19/54/20322\">",
"     image 1",
"    </a>",
"    ). Some studies have reported an association between the presence of intraamniotic debris and intraamniotic inflammation, preterm delivery, and other pregnancy complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link&amp;anchor=H10#H10\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Amniocentesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prior successful outcome after cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolongation of pregnancy after cerclage does not prove a diagnosis of cervical insufficiency because many pregnancies with premature cervical effacement have good outcomes in the absence of surgical intervention. As discussed above, in randomized trials and controlled studies, about 60 percent of women with a history of early preterm birth or recurrent late miscarriage maintain cervical length above 25 mm and have low rates of recurrent preterm",
"    <span class=\"nowrap\">",
"     birth/loss",
"    </span>",
"    without placement of a cerclage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/30,44,51-55\">",
"     30,44,51-55",
"    </a>",
"    ]. Therefore, repeat cerclage in subsequent pregnancies is not mandatory.",
"   </p>",
"   <p>",
"    In women who received a cerclage in a prior pregnancy without an appropriate indication, especially those who, after removal of cerclage at 36 to 37 weeks, did not go into labor in the subsequent two weeks, the risk of preterm birth in a subsequent pregnancy probably does not warrant a history-indicated cerclage; instead we suggest TVU cervical length screening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263426915\">",
"    <span class=\"h2\">",
"     Prior unsuccessful outcome after cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal cerclage may be successful in women who deliver very preterm despite placement of a transvaginal cerclage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32532?source=see_link\">",
"     \"Transabdominal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal pessaries are intended to alter the axis of the cervical canal and displace the weight of the uterine contents away from the cervix. By changing the angle of the cervix in relation to the uterus, the pessary also obstructs the internal os and thus may provide protection against ascending infection.",
"   </p>",
"   <p>",
"    A review of the literature on this topic before 2010 did not identify any well-designed randomized trials evaluating the benefit of cervical pessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/56\">",
"     56",
"    </a>",
"    ]. A few observational studies suggested that pessaries may have efficacy equivalent to cerclage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2012, a multicenter trial randomly assigned 385 pregnant women with cervical length &le;25 mm at 20 to 23 weeks to use of a cervical pessary or expectant management (no pessary) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/61\">",
"     61",
"    </a>",
"    ]. The majority of these patients (89 percent) had no history of previous preterm birth and none were treated with progestogens or cerclage. The pessary group had a significant reduction in spontaneous preterm &lt;28 weeks",
"    <span class=\"nowrap\">",
"     (4/190",
"    </span>",
"    [2 percent] versus",
"    <span class=\"nowrap\">",
"     16/190",
"    </span>",
"    [8 percent] OR 0.23, 95% CI 0.06-0.74) and &lt;34 weeks",
"    <span class=\"nowrap\">",
"     (12/190",
"    </span>",
"    [6 percent] versus",
"    <span class=\"nowrap\">",
"     51/190",
"    </span>",
"    [27 percent] OR 0.18, 95% CI 0.08-0.37).",
"   </p>",
"   <p>",
"    No adverse effects were noted, other than vaginal discharge and mild discomfort upon insertion. Use of a pessary to prolong pregnancy in women with a short cervical length may be an effective, inexpensive, and easy to implement intervention; however, given the open-label design with lack of a placebo control and the relatively small number of preterm births accounting for the dramatic results, we do not recommend implementation of this approach instead of cerclage or progestogens until these data are confirmed by additional randomized and placebo-controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18190027\">",
"    <span class=\"h2\">",
"     Indomethacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of data from three randomized cerclage trials found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy for asymptomatic women with a short cervix (&lt;25 mm) at 14 to 27 weeks who did not receive a cerclage did not reduce the risk of spontaneous preterm birth &lt;35 weeks, but appeared to reduce the risk of preterm birth &lt;24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/62\">",
"     62",
"    </a>",
"    ]. Further research including larger numbers and a randomized trial design is necessary to further clarify the effectiveness, as well as the risks, of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2537929\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence to recommend antibiotics for women with cervical insufficiency, based on poor obstetrical history, short TVU cervical length, or dilated cervix on physical exam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Lifestyle interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifestyle interventions (cessation of work and exercise, abstinence from coitus,",
"    <span class=\"nowrap\">",
"     bedrest/limited",
"    </span>",
"    activity) have not been adequately evaluated by well-designed studies. Although coitus is not a risk factor for onset of labor in women at term who are scheduled for induction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/63\">",
"     63",
"    </a>",
"    ], there are inadequate data on the safety of coitus in women at risk for preterm birth because of previous preterm birth or preterm cervical ripening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4457/abstract/64\">",
"     64",
"    </a>",
"    ]. Clinicians should consider the available evidence and the patient's individual circumstances when making lifestyle recommendations. In our practice, we advise women with both a prior preterm birth and a short cervix to avoid coitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical insufficiency describes a presumed physical weakness of cervical tissue that causes or contributes to the early delivery of an otherwise healthy pregnancy, usually in the second trimester. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical insufficiency may be congenital or acquired. Women at risk include those with a history of cervical trauma (eg, dilation and curettage, dilation and evacuation), collagen disorders, or congenital anomalies of the",
"      <span class=\"nowrap\">",
"       uterus/cervix.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7413900\">",
"       'Cervical risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cervical insufficiency is either based on historic factors or on a combination of historic factors and transvaginal ultrasound (TVU) measurement of cervical length. (See",
"      <a class=\"local\" href=\"#H15848061\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Using historic factors alone, cervical insufficiency is defined as painless cervical dilatation leading to recurrent second trimester pregnancy",
"      <span class=\"nowrap\">",
"       losses/births.",
"       <strong>",
"       </strong>",
"      </span>",
"      <br/>",
"      <br/>",
"      A preferable definition allows the diagnosis of cervical insufficiency during any pregnancy. Using this definition, cervical insufficiency is defined by TVU cervical length &lt;25 mm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced cervical changes on physical examination before 24 weeks of gestation in women with either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or more prior pregnancy",
"      <span class=\"nowrap\">",
"       losses/births",
"      </span>",
"      at 14 to 36 weeks,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Other significant risk factors for cervical insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with two or more consecutive prior second trimester pregnancy losses or three or more early preterm births who have risk factors for cervical insufficiency and in whom other causes of preterm birth have been excluded, we recommend history-indicated cerclage (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14004814\">",
"       'Candidates for history-indicated cerclage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with suspected cervical insufficiency and prior early preterm birth who do not meet criteria for history-indicated cerclage, sonographic surveillance should be started early in pregnancy (eg, 14 to 16 weeks). We suggest cerclage for women who develop a short cervix (&lt;25 mm) before 24 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14004837\">",
"       'Candidates for ultrasound surveillance and possible ultrasound indicated cerclage'",
"      </a>",
"      above.) Vaginal progesterone administration or placement of a pessary are alternative approaches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419366#H14419366\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Short cervix in current pregnancy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H26\">",
"       'Pessary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend progesterone supplementation for women with singleton gestations and a history of spontaneous preterm birth (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link\">",
"       \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/1\">",
"      Iwahashi M, Muragaki Y, Ooshima A, Umesaki N. Decreased type I collagen expression in human uterine cervix during pregnancy. J Clin Endocrinol Metab 2003; 88:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/2\">",
"      Warren JE, Silver RM, Dalton J, et al. Collagen 1Alpha1 and transforming growth factor-beta polymorphisms in women with cervical insufficiency. Obstet Gynecol 2007; 110:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/3\">",
"      Leduc L, Wasserstrum N. Successful treatment with the Smith-Hodge pessary of cervical incompetence due to defective connective tissue in Ehlers-Danlos syndrome. Am J Perinatol 1992; 9:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/4\">",
"      Larsson LG, Baum J, Mudholkar GS, Srivastava DK. Hypermobility: prevalence and features in a Swedish population. Br J Rheumatol 1993; 32:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/5\">",
"      Rackow BW, Arici A. Reproductive performance of women with m&uuml;llerian anomalies. Curr Opin Obstet Gynecol 2007; 19:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/6\">",
"      Chan YY, Jayaprakasan K, Tan A, et al. Reproductive outcomes in women with congenital uterine anomalies: a systematic review. Ultrasound Obstet Gynecol 2011; 38:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/7\">",
"      Kaufman RH, Adam E, Hatch EE, et al. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. Obstet Gynecol 2000; 96:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/8\">",
"      Vyas NA, Vink JS, Ghidini A, et al. Risk factors for cervical insufficiency after term delivery. Am J Obstet Gynecol 2006; 195:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/9\">",
"      Johnstone FD, Beard RJ, Boyd IE, McCarthy TG. Cervical diameter after suction termination of pregnancy. Br Med J 1976; 1:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/10\">",
"      Shah PS, Zao J, Knowledge Synthesis Group of Determinants of preterm/LBW births. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. BJOG 2009; 116:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/11\">",
"      Zhou W, S&oslash;rensen HT, Olsen J. Induced abortion and low birthweight in the following pregnancy. Int J Epidemiol 2000; 29:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/12\">",
"      Henriet L, Kaminski M. Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. BJOG 2001; 108:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/13\">",
"      Ol&aacute;h KS, Gee H. The prevention of preterm delivery--can we afford to continue to ignore the cervix? Br J Obstet Gynaecol 1992; 99:278.",
"     </a>",
"    </li>",
"    <li>",
"     Romero, R, Lockwood, CJ. Pathogenesis of spontaneous preterm labor. In: Creasy &amp; Resnik's Maternal Fetal Medicine, Creasy, RK, Resnik, R, Iams, JD, Lockwood, CJ, Moore, TR (Eds), Saunders, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/15\">",
"      Guzman ER, Mellon C, Vintzileos AM, et al. Longitudinal assessment of endocervical canal length between 15 and 24 weeks' gestation in women at risk for pregnancy loss or preterm birth. Obstet Gynecol 1998; 92:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/16\">",
"      Owen J, Yost N, Berghella V, et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA 2001; 286:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/17\">",
"      Macdonald R, Smith P, Vyas S. Cervical incompetence: the use of transvaginal sonography to provide an objective diagnosis. Ultrasound Obstet Gynecol 2001; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/18\">",
"      Andrews WW, Copper R, Hauth JC, et al. Second-trimester cervical ultrasound: associations with increased risk for recurrent early spontaneous delivery. Obstet Gynecol 2000; 95:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/19\">",
"      Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists multicentre randomised trial of cervical cerclage. MRC/RCOG Working Party on Cervical Cerclage. Br J Obstet Gynaecol 1993; 100:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/20\">",
"      BUCKINGHAM JC, BUETHE RA Jr, DANFORTH DN. COLLAGEN-MUSCLE RATIO IN CLINICALLY NORMAL AND CLINICALLY INCOMPETENT CERVICES. Am J Obstet Gynecol 1965; 91:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/21\">",
"      Leppert PC, Yu SY, Keller S, et al. Decreased elastic fibers and desmosine content in incompetent cervix. Am J Obstet Gynecol 1987; 157:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/22\">",
"      Rechberger T, Uldbjerg N, Oxlund H. Connective tissue changes in the cervix during normal pregnancy and pregnancy complicated by cervical incompetence. Obstet Gynecol 1988; 71:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/23\">",
"      da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/24\">",
"      Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/25\">",
"      Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989; 96:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/26\">",
"      Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/27\">",
"      Crane JM, Hutchens D. Transvaginal sonographic measurement of cervical length to predict preterm birth in asymptomatic women at increased risk: a systematic review. Ultrasound Obstet Gynecol 2008; 31:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/28\">",
"      Berghella V, Rafael TJ, Szychowski JM, et al. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011; 117:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/29\">",
"      Berghella V, Mackeen AD. Cervical length screening with ultrasound-indicated cerclage compared with history-indicated cerclage for prevention of preterm birth: a meta-analysis. Obstet Gynecol 2011; 118:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/30\">",
"      Owen J, Hankins G, Iams JD, et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201:375.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/31\">",
"      Berghella V, Talucci M, Desai A. Does transvaginal sonographic measurement of cervical length before 14 weeks predict preterm delivery in high-risk pregnancies? Ultrasound Obstet Gynecol 2003; 21:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/32\">",
"      Iams JD, Cebrik D, Lynch C, et al. The rate of cervical change and the phenotype of spontaneous preterm birth. Am J Obstet Gynecol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/33\">",
"      Rafael TJ, Mackeen AD, Berghella V. The effect of 17&alpha;-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage. Am J Perinatol 2011; 28:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/34\">",
"      Rebarber A, Cleary-Goldman J, Istwan NB, et al. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Am J Perinatol 2008; 25:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/35\">",
"      Berghella V, Figueroa D, Szychowski JM, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010; 202:351.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/36\">",
"      Conde-Agudelo A, Romero R, Nicolaides K, et al. Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol 2013; 208:42.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/37\">",
"      Visintine J, Berghella V, Henning D, Baxter J. Cervical length for prediction of preterm birth in women with multiple prior induced abortions. Ultrasound Obstet Gynecol 2008; 31:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/38\">",
"      Airoldi J, Berghella V, Sehdev H, Ludmir J. Transvaginal ultrasonography of the cervix to predict preterm birth in women with uterine anomalies. Obstet Gynecol 2005; 106:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/39\">",
"      Berghella V, Pereira L, Gariepy A, Simonazzi G. Prior cone biopsy: prediction of preterm birth by cervical ultrasound. Am J Obstet Gynecol 2004; 191:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/40\">",
"      Berghella V, Roman A, Daskalakis C, et al. Gestational age at cervical length measurement and incidence of preterm birth. Obstet Gynecol 2007; 110:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/41\">",
"      Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012; 206:124.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/42\">",
"      Cahill AG, Odibo AO, Caughey AB, et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010; 202:548.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/43\">",
"      Werner EF, Han CS, Pettker CM, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol 2011; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/44\">",
"      Althuisius SM, Dekker GA, van Geijn HP, et al. Cervical incompetence prevention randomized cerclage trial (CIPRACT): study design and preliminary results. Am J Obstet Gynecol 2000; 183:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/45\">",
"      Pereira L, Cotter A, G&oacute;mez R, et al. Expectant management compared with physical examination-indicated cerclage (EM-PEC) in selected women with a dilated cervix at 14(0/7)-25(6/7) weeks: results from the EM-PEC international cohort study. Am J Obstet Gynecol 2007; 197:483.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/46\">",
"      Daskalakis G, Papantoniou N, Mesogitis S, Antsaklis A. Management of cervical insufficiency and bulging fetal membranes. Obstet Gynecol 2006; 107:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/47\">",
"      Kusanovic JP, Espinoza J, Romero R, et al. Clinical significance of the presence of amniotic fluid 'sludge' in asymptomatic patients at high risk for spontaneous preterm delivery. Ultrasound Obstet Gynecol 2007; 30:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/48\">",
"      Espinoza J, Gon&ccedil;alves LF, Romero R, et al. The prevalence and clinical significance of amniotic fluid 'sludge' in patients with preterm labor and intact membranes. Ultrasound Obstet Gynecol 2005; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/49\">",
"      Bujold E, Pasquier JC, Simoneau J, et al. Intra-amniotic sludge, short cervix, and risk of preterm delivery. J Obstet Gynaecol Can 2006; 28:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/50\">",
"      Gorski LA, Huang WH, Iriye BK, Hancock J. Clinical implication of intra-amniotic sludge on ultrasound in patients with cervical cerclage. Ultrasound Obstet Gynecol 2010; 36:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/51\">",
"      Guzman ER, Forster JK, Vintzileos AM, et al. Pregnancy outcomes in women treated with elective versus ultrasound-indicated cervical cerclage. Ultrasound Obstet Gynecol 1998; 12:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/52\">",
"      To MS, Palaniappan V, Skentou C, et al. Elective cerclage vs. ultrasound-indicated cerclage in high-risk pregnancies. Ultrasound Obstet Gynecol 2002; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/53\">",
"      Groom KM, Bennett PR, Golara M, et al. Elective cervical cerclage versus serial ultrasound surveillance of cervical length in a population at high risk for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2004; 112:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/54\">",
"      Byrd JR, McDonough PG. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion. Fertil Steril 1979; 32:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/55\">",
"      Harger JH. Cervical cerclage: patient selection, morbidity, and success rates. Clin Perinatol 1983; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/56\">",
"      Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA. Cervical pessary for preventing preterm birth. Cochrane Database Syst Rev 2010; :CD007873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/57\">",
"      Arabin B, Halbesma JR, Vork F, et al. Is treatment with vaginal pessaries an option in patients with a sonographically detected short cervix? J Perinat Med 2003; 31:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/58\">",
"      Antczak-Judycka A, Sawicki W, Spiewankiewicz B, et al. [Comparison of cerclage and cerclage pessary in the treatment of pregnant women with incompetent cervix and threatened preterm delivery]. Ginekol Pol 2003; 74:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/59\">",
"      Acharya G, Eschler B, Gr&oslash;nberg M, et al. Noninvasive cerclage for the management of cervical incompetence: a prospective study. Arch Gynecol Obstet 2006; 273:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/60\">",
"      Alfirevic Z, Owen J, Carreras Moratonas E, et al. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. Ultrasound Obstet Gynecol 2013; 41:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/61\">",
"      Goya M, Pratcorona L, Merced C, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet 2012; 379:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/62\">",
"      Berghella V, Rust OA, Althuisius SM. Short cervix on ultrasound: does indomethacin prevent preterm birth? Am J Obstet Gynecol 2006; 195:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/63\">",
"      Tan PC, Yow CM, Omar SZ. Effect of coital activity on onset of labor in women scheduled for labor induction: a randomized controlled trial. Obstet Gynecol 2007; 110:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4457/abstract/64\">",
"      Yost NP, Owen J, Berghella V, et al. Effect of coitus on recurrent preterm birth. Obstet Gynecol 2006; 107:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6774 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4457=[""].join("\n");
var outline_f4_22_4457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7413947\">",
"      Past obstetrical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7413900\">",
"      Cervical risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7413547\">",
"      - Congenital factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7413555\">",
"      - Acquired factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7413977\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263423507\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263423514\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263428260\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15848061\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263427240\">",
"      Can cervical insufficiency be diagnosed before pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25211294\">",
"      Women with prior pregnancy losses or preterm births",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14004814\">",
"      - Candidates for history-indicated cerclage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14004837\">",
"      - Candidates for ultrasound surveillance and possible ultrasound indicated cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7414928\">",
"      Women with singleton pregnancy, no prior birth, but risk factors for cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Short cervix at &lt;24 weeks, no prior preterm birth, no risk factors for preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89361408\">",
"      Physical examination reveals a dilated cervix and visible membranes before 24 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prior successful outcome after cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263426915\">",
"      Prior unsuccessful outcome after cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18190027\">",
"      Indomethacin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2537929\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Lifestyle interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6774|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/54/20322\" title=\"diagnostic image 1\">",
"      Ultrasound image of membrane separation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/57/924\" title=\"table 1\">",
"      Management of women with previous PTD or 2nd trimester loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/33/19995\" title=\"table 2\">",
"      Protocol for cervical length screening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/52/16200?source=related_link\">",
"      Cervical intraepithelial neoplasia: Reproductive effects of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32532?source=related_link\">",
"      Transabdominal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4458="Megakaryocyte biology and the production of platelets";
var content_f4_22_4458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Megakaryocyte biology and the production of platelets",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4458/contributors\">",
"     David J Kuter, MD, DPhil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4458/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/22/4458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/22/4458/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/22/4458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The megakaryocyte is a novel mammalian cell that produces platelets. Evidence for this relationship was first provided in 1906 by James Homer Wright who demonstrated that circulating platelets and a giant bone marrow cell now known to be the megakaryocyte shared common tinctorial properties when subjected to a modified Romanofsky stain (",
"    <a class=\"graphic graphic_picture graphicRef67199 \" href=\"UTD.htm?23/53/24402\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/1\">",
"     1",
"    </a>",
"    ]. Wright went on to show that megakaryocytes sent out pseudopodia into the bone marrow sinusoids from which platelets appeared to be shed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This model of how megakaryocytes produce platelets remains with us to this day. Wright also demonstrated in normal and abnormal human physiology that changes in platelet number were associated only with changes in the megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/2\">",
"     2",
"    </a>",
"    ]. Since these seminal observations, much has become known about megakaryocytes and how they produce platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The characteristics of megakaryocytes, how they regulate platelet production, and their role in pathologic processes will be described here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In lower vertebrate species such as fish and birds, all the circulating blood cells, including the erythrocytes and the platelets (called thrombocytes), are nucleated and are produced by diploid bone precursor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/5\">",
"     5",
"    </a>",
"    ]. However, in higher vertebrates, platelets are produced by a different mechanism whose evolutionary advantage is unclear. Enucleate platelets are generated from bone marrow megakaryocytes that have a number of unique properties.",
"   </p>",
"   <p>",
"    In humans, megakaryocytes normally account for approximately 0.05 to 0.1 percent of all nucleated bone marrow cells. Their number increases as the demand for platelets rises. In contrast to the erythrocyte, which has a diameter of 7 to 8 microns and a volume of 85 to 100 fL, megakaryocytes have an average diameter of 20 to 25 microns and a volume of 4700 &plusmn; 100 fL (",
"    <a class=\"graphic graphic_picture graphicRef50650 \" href=\"UTD.htm?28/8/28804\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/6\">",
"     6",
"    </a>",
"    ]. Some of the largest megakaryocytes have diameters of 50 to 60 microns and volumes of 65,000 to 100,000 fL.",
"   </p>",
"   <p>",
"    Each megakaryocyte produces a total of 1000 to 3000 platelets. Although it has long been assumed that larger megakaryocytes make more platelets, this has never been conclusively demonstrated.",
"   </p>",
"   <p>",
"    In addition to some hepatocytes and macrophages, which occasionally have two to four times the normal diploid content of DNA, mature megakaryocytes are invariably polyploid and contain from two (4N) to 32 (64N) times the normal diploid amount of DNA; the mean value is 16N in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This polyploidy appears to result in functional gene amplification, perhaps to increase protein synthesis in parallel with megakaryocyte enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the polyploid hepatocytes and macrophages whose DNA is contained in multiple separate nuclei, all of the DNA in the megakaryocytes is contained within one highly lobulated nuclear envelope in which each lobule represents one diploid amount (2N) of DNA. This is the result of a process referred to as endomitosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surface membrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;The megakaryocyte surface membrane is similar to that of the platelet. One of the first signs of differentiation along the megakaryocyte lineage is the appearance on the surface of the megakaryocyte of the platelet glycoprotein (GP) receptor",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    and later by von Willebrand factor, GPIb, and collagen receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The megakaryocyte has a demarcation membrane system in which the surface membrane of the mature megakaryocyte is deeply invaginated and highly redundant (",
"    <a class=\"graphic graphic_picture graphicRef81336 \" href=\"UTD.htm?36/29/37335\">",
"     picture 3",
"    </a>",
"    ). This enormous amplification of the surface membrane is thought to be the means by which an adequate amount of platelet surface membrane is created and subsequently used to form platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific platelet granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since platelets undergo little protein synthesis, their cytoplasmic characteristics are mostly determined by the megakaryocytes from which they arise. The membrane bodies of the alpha and dense platelet granules and some of their contents are made in megakaryocytes. However, some of the granule contents are actually taken up from the plasma by both megakaryocytes and platelets.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha granules of platelets contain numerous platelet proteins and growth factors. The granule body itself is made early in megakaryocyte development before the demarcation membrane system. Some of the granule contents such as platelet-derived growth factor, transforming growth factor-beta, platelet factor-4, and von Willebrand factor are synthesized in the megakaryocyte and transported to the alpha granules [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/17\">",
"       17",
"      </a>",
"      ]. However, other proteins enter the alpha granules of both megakaryocytes and platelets from the plasma via",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor-mediated endocytosis (fibrinogen) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/18-20\">",
"       18-20",
"      </a>",
"      ] or pinocytosis (eg, albumin and IgG) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dense granules of platelets are physically dense and, because they contain serotonin and calcium, are also electron dense when seen with the transmission electron microscope. The dense granule membrane bodies are made in megakaryocytes but do not acquire their content of serotonin and calcium until platelets are released into the circulation where they take up calcium and most of the body's circulating serotonin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microscopic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large, mature, polyploid megakaryocytes are readily identified by light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef67199 \" href=\"UTD.htm?23/53/24402\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50650 \" href=\"UTD.htm?28/8/28804\">",
"     picture 2",
"    </a>",
"    ). On occasion, they can be seen to be shedding platelets.",
"   </p>",
"   <p>",
"    In addition to the mature megakaryocytes, two other stages of megakaryocytes may be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/24\">",
"     24",
"    </a>",
"    ]. Intermediate megakaryocytes have large polyploid nuclei but a modest amount of cytoplasm; they can be distinguished from immature megakaryocytes which have scant cytoplasm and large, basophilic nuclei. Also present, but identified only by special stains for von Willebrand factor or glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    are small, diploid, lymphocyte-like megakaryocyte progenitor cells that have not yet undergone endomitosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like all other bone marrow cells, megakaryocytes are derived from the pluripotential stem cell (",
"    <a class=\"graphic graphic_figure graphicRef74886 \" href=\"UTD.htm?24/60/25550\">",
"     figure 1",
"    </a>",
"    ). The stem cell gives rise to early bilineage progenitors (megakaryocyte-erythroid progenitors, BEP) that are subsequently able to undergo erythrocyte or megakaryocyte differentiation. Although there is no specific assay for this common megakaryocyte-erythroid progenitor cell, its existence is supported by several lines of evidence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mice in which the thymidine kinase gene was expressed under the control of the GPIIb promoter, administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (which is converted to the toxic monophosphate by thymidine kinase) resulted in eradication of both megakaryocyte and erythroid progenitors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/26\">",
"       26",
"      </a>",
"      ]. This observation suggests that the GPIIb promoter was transcriptionally active in this bipotential progenitor cell [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/27\">",
"       27",
"      </a>",
"      ] and possibly in a totipotent progenitor cell [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a close relationship between early erythroid and megakaryocyte differentiation at the molecular, cellular, and pathological levels. As an example, common transcription factors exist in these two lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/29\">",
"     29",
"    </a>",
"    ] and their regulatory hematopoietic cytokines, erythropoietin and thrombopoietin, are 50 percent similar (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been demonstrated that a microRNA, miR-150, is important in the lineage specification that occurs to this common megakaryocyte-erythroid progenitor cell. When present, miR-150 drives differentiation towards megakaryocytes and away from erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/31\">",
"     31",
"    </a>",
"    ]. The transcription factor Myb is a critical target of miR-150 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/32\">",
"     32",
"    </a>",
"    ]. Thrombopoietin increases miR-150, which in turn binds to the 4 miR-150 binding sites on the c-Myb 3&rsquo;UTR and decreases Myb mRNA and protein. Reduction in Myb expression subsequently leads to increased megakaryocyte differentiation and reduced erythroid differentiation. When miR-150 is absent, erythroid differentiation occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultimately the differentiation process produces a precursor cell committed only to megakaryocyte differentiation called the megakaryocyte colony-forming cell (Meg-CFC) which can be assayed by cell culture methods. This cell expresses some megakaryocyte properties such as the presence of glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and undergoes mitosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/36\">",
"     36",
"    </a>",
"    ]. It is stimulated by interleukin (IL-3) and thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eventually the Meg-CFC stops mitosis and enters endomitosis in which DNA replication continues, but neither the nucleus nor the cell undergoes division (cytokinesis). Polyploid precursors with scant cytoplasm are produced (",
"    <a class=\"graphic graphic_figure graphicRef74886 \" href=\"UTD.htm?24/60/25550\">",
"     figure 1",
"    </a>",
"    ). It was initially assumed that endomitosis was simply the absence of mitosis after each round of DNA replication. However, studies in mice showed that megakaryocytes enter mitosis and progress through normal prophase, prometaphase, metaphase, and up to anaphase A, but not to anaphase B, telophase, or cytokinesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/39\">",
"     39",
"    </a>",
"    ]. After anaphase, the nuclear membrane is reassembled about the sister chromatids as a single nucleus skipping telophase and cytokinesis; the cells then enter the next round of DNA replication.",
"   </p>",
"   <p>",
"    Genes with known roles in regulating the cell cycle such as the cyclin-dependent kinases (CDKs) and the cyclins have been studied. Although the results are incomplete, endomitosis is associated with increased cyclin D3 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/40\">",
"     40",
"    </a>",
"    ] and reduced levels of cyclin B1 and cyclin B1-dependent Cdc2 kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/41\">",
"     41",
"    </a>",
"    ]. These events may allow the megakaryocyte to abort mitosis and reenter a phase of DNA replication without cytokinesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon the completion of endomitosis, the immature megakaryocytes develop a mature cytoplasm, become morphologically identifiable, and eventually release platelets. Overall, it takes approximately five to seven days to progress from the megakaryocyte colony-forming cell (Meg-CFC) to the platelet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin has a major effect on almost all steps of megakaryocyte differentiation and maturation. It promotes the growth of Meg-CFC, dramatically increases the rate of endomitosis, inhibits apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and stimulates megakaryocyte maturation. An increase in megakaryocyte ploidy is seen at even the lowest amounts of thrombopoietin and is one of the earliest demonstrable effects of thrombopoietin. Other cytokines such as IL-3 and IL-11 can also promote Meg-CFC growth and megakaryocyte maturation but have little effect on endomitosis; these actions may not be important in normal physiology. However, the final stage of platelet release is not dependent on thrombopoietin and actually may be inhibited by large amounts of thrombopoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular mechanisms by which cells become committed to the megakaryocyte lineage are just starting to be unraveled. Unlike hematopoietic growth factors, such as thrombopoietin, which appear to prevent apoptosis and stimulate growth of cells already committed to megakaryocyte differentiation, intrinsic lineage-specific transcription factors are expressed in cells and then establish cell-specific phenotypes. The transcription factors GATA-1 and NF-E2 are important for megakaryocyte development. What lineage-specific genes are controlled by these factors remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     GATA-1 transcription factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;GATA-1 is zinc-finger transcription factor which is expressed in erythroid, megakaryocyte, eosinophil, and mast cells. Elimination of the entire GATA-1 gene results in embryonic death due to severe anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since GATA-1 is found in the megakaryocyte and GATA-1 binding sites are found on many megakaryocyte and platelet genes, it was anticipated that GATA-1 played a role in megakaryocyte proliferation and development [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/47\">",
"     47",
"    </a>",
"    ]. When a unique portion of the GATA-1 promoter was disrupted, GATA-1 expression was eliminated in megakaryocytes but not in erythrocytes. These nonanemic animals had a platelet count 15 percent of normal and an increased number of small, abnormal megakaryocytes with multilobulated nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/48\">",
"     48",
"    </a>",
"    ]. The megakaryocytes had scant cytoplasm, few demarcation membranes, no platelet \"territories,\" and few platelet granules. These findings suggest an early defect in cytoplasmic maturation, with a subsequent fall in platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H10#H10\">",
"     \"Regulation of erythropoiesis\", section on 'GATA-1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous genes are downregulated by the loss of GATA-1 in mice, including JAK2 and STAT-1, which mediate thrombopoietin and interferon-gamma (IF-gamma) signaling pathways, respectively. It has been suggested that GATA-1 promotes megakaryopoiesis in part via activation of",
"    <span class=\"nowrap\">",
"     IF-gamma/STAT1",
"    </span>",
"    signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/49\">",
"     49",
"    </a>",
"    ], possibly explaining the mechanism by which various inflammatory disorders can cause elevated platelet counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     NF-E2 transcription factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;NF-E2 (nuclear factor erythroid derived 2) is a heterodimeric basic leucine zipper transcription factor that is composed of a widely expressed p18 subunit and a p45 subunit present only in erythroid, megakaryocyte, and mast cells. When NF-E2 is disrupted, mice develop a mild anemia and a profound thrombocytopenia associated with a high rate of early hemorrhagic death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These mice have adequate numbers of large, abnormal megakaryocytes with hyperlobulated nuclei, rare granules, adequate amounts of demarcation membranes, but no platelet \"territories.\" In addition, they never produce proplatelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/52\">",
"     52",
"    </a>",
"    ]. Proplatelets are elongated strands of megakaryocyte cytoplasm that are larger than normal platelets and later fragment into a number of platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Thus, NF-E2 appears to affect megakaryocyte cytoplasmic differentiation and platelet production at a somewhat later step than GATA-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PLATELET FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although historically one of the first observations was the apparent shedding of platelets by megakaryocytes, the exact mechanism by which platelets are produced remains unclear. A number of different mechanisms have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The megakaryocyte cytoplasm is divided by the demarcation membrane system into future platelet \"territories\" and the megakaryocyte simply fractures into separate platelets (",
"      <a class=\"graphic graphic_picture graphicRef81336 \" href=\"UTD.htm?36/29/37335\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/56\">",
"       56",
"      </a>",
"      ]. The platelets would be released into the marrow and then somehow pass into the sinusoids, leaving behind the bare megakaryocyte nucleus. Support for this hypothesis comes primarily from electron microscopic data showing these platelet territories in megakaryocytes but not the more dynamic process of fracturing into platelets. However, few bare megakaryocyte nuclei are seen in the bone marrow and there is no evidence that platelets pass through the endothelial cells lining the sinusoids.",
"     </li>",
"     <li>",
"      Megakaryocytes use the highly redundant demarcation membrane system to send pseudopodia out into the bone marrow sinusoids [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/13,14,53\">",
"       13,14,53",
"      </a>",
"      ], and platelets and proplatelets then bud off, possibly as a result of localized caspase activation (",
"      <a class=\"graphic graphic_picture graphicRef73160 \" href=\"UTD.htm?24/26/24993\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/57\">",
"       57",
"      </a>",
"      ]. The bone marrow sinusoids are lined by very thin endothelial cells that are tightly bound to each other and may even overlap [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/53\">",
"       53",
"      </a>",
"      ]. The megakaryocyte pseudopodia actually pass through, not between, the endothelial cells which may in turn play some role in regulating the process [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter of these is the mechanism initially suggested by Wright and most available data confirm many elements of this model:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice recovering from severe thrombocytopenia have increased numbers of proplatelet processes in the sinusoids [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mice lacking the transcription factor NF-E2 have severe thrombocytopenia that is probably related to the inability of the megakaryocytes to form proplatelet processes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/52,58\">",
"       52,58",
"      </a>",
"      ]. A similar defect occurs in mice with selective loss of the transcription factor GATA-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In vitro and in vivo work has demonstrated the molecular mechanisms that result in proplatelet formation from megakaryocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/59\">",
"       59",
"      </a>",
"      ]. Cytoskeletal reorganization produces pseudopod by evagination of the demarcation membrane system, platelet granules then track into the elongating pseudopodia, and the proplatelet fragments are released.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemoattractants such as stromal-derived factor 1, induce metalloproteinase production by megakaryocytes that is necessary for transendothelial migration and platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/44,60\">",
"     44,60",
"    </a>",
"    ]. Studies in animals have suggested that while TPO supports progenitor cell expansion, chemokine-mediated interaction of these progenitors with the bone marrow vascular niche allows them to relocate to a microenvironment that is permissive for megakaryocyte maturation and thrombopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/61\">",
"     61",
"    </a>",
"    ]. SDF-1 may induce megakaryocytes to migrate to the bone marrow sinusoid where proplatelet formation occurs.",
"   </p>",
"   <p>",
"    Megakaryocytes or proplatelets are released from the bone marrow and travel to the lung where they are transformed into platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. This model is a further elaboration of the preceding model in which the locus of the production of single platelets is not in the bone marrow but in the lungs. Evidence for this mechanism includes the demonstration that megakaryocytes can cross the bone marrow endothelial cell barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/26\">",
"     26",
"    </a>",
"    ] and detection of megakaryocytes and megakaryocyte nuclei in the circulation and in the pulmonary vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. Whether these are simply occasional errant megakaryocytes that have escaped from the marrow and become trapped in the lungs or reflect a major route of cell trafficking is unclear.",
"   </p>",
"   <p>",
"    The log-normal distribution of platelet sizes has long suggested that megakaryocytes or large fragments of megakaryocytes are cleaved in the circulation into platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/63\">",
"     63",
"    </a>",
"    ]. It has been estimated that the total amount of pulmonary megakaryocytes may account for most of platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/65\">",
"     65",
"    </a>",
"    ], but direct evidence for this is still lacking.",
"   </p>",
"   <p>",
"    Many questions regarding the nuances of the production of platelets from megakaryocytes have not been clearly answered. Incomplete data suggest that platelets are not shed from megakaryocytes with ploidy less than 8N and that larger megakaryocytes make more platelets than smaller ones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/66\">",
"     66",
"    </a>",
"    ]. In general, there is a relationship between increased ploidy and increased megakaryocyte size but, given the time needed for megakaryocytes to mature cytoplasmically, not all small megakaryocytes are of low ploidy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     REGULATION OF PLATELET PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past 60 years, a number of principles of the regulation of platelet production have emerged from clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The platelet count in any individual remains constant throughout life unless perturbed by physiologic (eg, pregnancy) or pathologic (eg, myelodysplasia) processes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a large variation in the platelet count among normal individuals, which ranges approximately three-fold, from 150,000 to",
"      <span class=\"nowrap\">",
"       450,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/69\">",
"       69",
"      </a>",
"      ]. This is different from the erythrocyte count which shows much less variability.",
"     </li>",
"     <li>",
"      There is an inverse relationship between the normal platelet count and the normal mean platelet volume (MPV) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/70\">",
"       70",
"      </a>",
"      ], resulting in a roughly constant circulating platelet mass [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/71\">",
"       71",
"      </a>",
"      ]. This inverse relationship extends to other species and is an example of \"phylogenic canalization\" [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/72\">",
"       72",
"      </a>",
"      ]. As an example, mice have a normal platelet count of",
"      <span class=\"nowrap\">",
"       1,200,000/microL",
"      </span>",
"      and an MPV of 2.1 fL whereas porcupines have a normal platelet count of",
"      <span class=\"nowrap\">",
"       30,000/microL",
"      </span>",
"      and an MPV of 105 fL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H8#H8\">",
"       \"Automated hematology instrumentation\", section on 'Mean platelet volume'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The body \"defends\" the total mass of platelets, not the platelet count. Approximately one-third of the total platelet mass is normally sequestered in an exchangeable splenic pool [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/73\">",
"       73",
"      </a>",
"      ]. In animals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/74,75\">",
"       74,75",
"      </a>",
"      ] or humans with enlarged spleens [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/73\">",
"       73",
"      </a>",
"      ], the platelet count decreases proportionally to the increase in the size of the spleen but the total body mass of platelets remains normal and unchanged.",
"     </li>",
"     <li>",
"      The bone marrow megakaryocytes respond to changes in the demand for platelets by altering their number, size, and ploidy. In animals made thrombocytopenic by the injection of antibody to platelets, bone marrow megakaryocytes increase their number, size (",
"      <a class=\"graphic graphic_picture graphicRef81722 \" href=\"UTD.htm?20/8/20614\">",
"       picture 5",
"      </a>",
"      ), and ploidy (",
"      <a class=\"graphic graphic_figure graphicRef69626 \" href=\"UTD.htm?16/27/16829\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/8,76,77\">",
"       8,76,77",
"      </a>",
"      ]; in animals made thrombocytotic by platelet transfusion, the opposite changes occur [",
"      <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/8,77\">",
"       8,77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the discovery of thrombopoietin, these clinical observations can now be explained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .) Thrombopoietin is produced at a constant rate by the liver and enters the circulation where most is removed by avid thrombopoietin (c-mpl) receptors on normal platelets and possibly some by bone marrow megakaryocytes. The residual amount of thrombopoietin (50 to 150",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    provides basal stimulation of megakaryocytes and a basal rate of platelet production.",
"   </p>",
"   <p>",
"    Since it is the total number of circulating platelet c-mpl receptors that determines the clearance of thrombopoietin, the constancy of the normal circulating platelet mass, not the platelet count, can now be explained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the platelet production rate decreases, as during thrombocytopenia following chemotherapy, the platelet mass and the amount of c-mpl receptors decreases, clearance of thrombopoietin falls, thrombopoietin concentrations rise, and megakaryocyte growth is stimulated.",
"     </li>",
"     <li>",
"      With experimental transfusion of platelets to levels above normal, the total platelet mass and amount of c-mpl receptors rise, thrombopoietin clearance is increased, thrombopoietin concentrations fall, and megakaryocyte growth decreases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When thrombopoietin or its receptor have been \"knocked-out\" by homologous recombination in mice, the megakaryocyte and platelet mass are reduced to approximately 10 percent of normal but the animals are healthy and do not spontaneously bleed (",
"    <a class=\"graphic graphic_figure graphicRef68869 \" href=\"UTD.htm?32/25/33181\">",
"     figure 3",
"    </a>",
"    ). The factors responsible for the residual platelet production in this setting are not well understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link&amp;anchor=H6#H6\">",
"     \"Biology and physiology of thrombopoietin\", section on 'Effects on platelet production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MEGAKARYOCYTES IN DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As initially described in part by Wright, characteristic changes in megakaryocytes are associated with several disease processes. Most of these clinical conditions have been evaluated by extensive bone marrow and platelet kinetic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombocytopenia that follows most chemotherapy is due to a reduced number of megakaryocytes, perhaps due to drug-induced apoptosis of stem cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    megakaryocyte progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/78\">",
"     78",
"    </a>",
"    ]. This results in an elevated plasma concentration of thrombopoietin that increases the average ploidy of the remaining megakaryocytes in an effort to increase platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/79\">",
"     79",
"    </a>",
"    ]. Platelet kinetic studies have also demonstrated some element of ineffective platelet production (ineffective thrombopoiesis) in this setting (",
"    <a class=\"graphic graphic_figure graphicRef79556 \" href=\"UTD.htm?18/17/18718\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However some chemotherapy drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) have little or no effect on bone marrow stem cells or megakaryocyte progenitor cells but produce thrombocytopenia by inhibiting platelet shedding from megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal platelets undergo apoptosis and their lifespan is regulated by apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. While no currently used chemotherapy drug appears to have this effect, several drugs in development (eg, ABT-737) inhibit Bcl2 and produce rapid and profound thrombocytopenia by causing platelets to undergo apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pernicious anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe pernicious anemia, the low platelet count (",
"    <a class=\"graphic graphic_figure graphicRef79556 \" href=\"UTD.htm?18/17/18718\">",
"     figure 4",
"    </a>",
"    ) is associated with a marked increase in the number of megakaryocytes (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    ) but diminished ploidy, resulting in an expanded megakaryocyte mass (",
"    <a class=\"graphic graphic_figure graphicRef60387 \" href=\"UTD.htm?29/32/30222\">",
"     figure 6",
"    </a>",
"    ) but reduced platelet production per megakaryocyte (",
"    <a class=\"graphic graphic_figure graphicRef74204 \" href=\"UTD.htm?6/13/6367\">",
"     figure 7",
"    </a>",
"    ). The ineffective platelet production from the megakaryocytes is comparable to the ineffective erythrocyte production also seen in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=see_link\">",
"     \"Physiology of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congestive splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the thrombocytopenia seen in splenomegaly secondary to liver disease is thought to be due to redistribution of part of the normal circulating mass of platelets from the circulation to the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/73,85\">",
"     73,85",
"    </a>",
"    ]. Platelet kinetic studies have demonstrated that the modest thrombocytopenia is",
"    <strong>",
"     not",
"    </strong>",
"    accompanied by a decrease in platelet survival (",
"    <a class=\"graphic graphic_figure graphicRef79556 \" href=\"UTD.htm?18/17/18718\">",
"     figure 4",
"    </a>",
"    ) but does give rise to a small increase in the number and ploidy of megakaryocytes (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    ) and a small overall increase in platelet production (",
"    <a class=\"graphic graphic_figure graphicRef60387 \" href=\"UTD.htm?29/32/30222\">",
"     figure 6",
"    </a>",
"    ). These results are at odds with recent data showing a reduced level of thrombopoietin and a reduction in platelet production rates in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immune thrombocytopenic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal models and in humans, chronic immune (idiopathic) thrombocytopenic purpura (ITP) is characterized by an increase in the number, size and ploidy of bone marrow megakaryocytes (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    ). One interpretation of these findings is that the decline in platelet mass in ITP leads to an initial rise in thrombopoietin levels which in turn stimulates megakaryocytopoiesis and increases platelet production.",
"   </p>",
"   <p>",
"    Support for this hypothesis comes from some early platelet kinetic studies in which these morphologic findings were associated with a six- to eightfold increase in the rate of platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/6,87,88\">",
"     6,87,88",
"    </a>",
"    ] and a shortened platelet survival time (",
"    <a class=\"graphic graphic_figure graphicRef79556 \" href=\"UTD.htm?18/17/18718\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74204 \" href=\"UTD.htm?6/13/6367\">",
"     figure 7",
"    </a>",
"    ). However, more recent platelet kinetic studies have failed to demonstrate an increase in platelet production in ITP and suggested that the morphologic findings might be related to ineffective platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. The observation that plasma TPO concentrations are normal in patients with ITP is consistent with either hypothesis.",
"   </p>",
"   <p>",
"    While these conflicting platelet kinetic studies reflect differences in methodology (eg,",
"    <sup>",
"     51",
"    </sup>",
"    Cr versus",
"    <sup>",
"     111",
"    </sup>",
"    In labeling of platelets) and patient populations studied, a new model of ITP is emerging: ITP is a disorder of increased platelet destruction and inappropriately low platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. ITP is characterized by antibody-mediated platelet destruction (primarily in the liver and spleen) and a compensatory increase in megakaryocyte number, size and ploidy. However, the increased platelet mass does not produce a significant increase in platelets because the anti-platelet antibody probably binds to the megakaryocytes and produces apoptosis, thereby preventing platelet shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/90,94\">",
"     90,94",
"    </a>",
"    ]. In addition cytotoxic T cells may directly inhibit megakaryocyte viability and decrease platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reactive thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive thrombocytosis occurs in association with iron deficiency, malignancy, and inflammatory states (",
"    <a class=\"graphic graphic_table graphicRef74148 \" href=\"UTD.htm?32/7/32892\">",
"     table 1",
"    </a>",
"    ). It is associated with an increased number of megakaryocytes but with average ploidy less than normal (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    ), an elevated megakaryocyte mass, and an enhanced rate of platelet production (",
"    <a class=\"graphic graphic_figure graphicRef60387 \" href=\"UTD.htm?29/32/30222\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74204 \" href=\"UTD.htm?6/13/6367\">",
"     figure 7",
"    </a>",
"    ). The increase in platelet count is probably secondary to the expansion of megakaryocyte number due to inflammatory cytokines such as interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. Ploidy is reduced because of a lower plasma concentration of thrombopoietin resulting from increased clearance by the expanded platelet mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the patient with thrombocytosis\", section on 'Other testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Essential thrombocythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In essential thrombocythemia (ET) and the related myeloproliferative disorders such as chronic myeloid leukemia and polycythemia vera (PV), there is a clonal proliferation of megakaryocytes that are of high ploidy and actively produce platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/99\">",
"     99",
"    </a>",
"    ]. Whether the normal regulatory mechanism via thrombopoietin and its receptor is functioning is unclear, although the finding of a specific mutation in JAK2 in about 50 percent of patients with ET and up to 100 percent of patients with PV is consistent with altered",
"    <span class=\"nowrap\">",
"     GATA-1-JAK/STAT",
"    </span>",
"    signaling. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'GATA-1 transcription factor'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'Mutations in PV, ET, and PMF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet kinetic data suggest the proliferation is autonomous of thrombopoietin since at increased platelet mass (",
"    <a class=\"graphic graphic_figure graphicRef79556 \" href=\"UTD.htm?18/17/18718\">",
"     figure 4",
"    </a>",
"    ) there is a greatly increased megakaryocyte ploidy (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    ) despite a normal or slightly elevated plasma thrombopoietin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. The latter finding is explained by the demonstration that platelet, and possibly megakaryocyte, thrombopoietin receptors are markedly reduced via an uncertain mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/101,102\">",
"     101,102",
"    </a>",
"    ], resulting in a net overall normal clearance of thrombopoietin at these elevated platelet counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Primary myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical finding in primary myelofibrosis (chronic idiopathic myelofibrosis) is an increase in bone marrow megakaryocytes with a large amount of fibrosis and occasional megakaryocyte dysplasia. The fibrotic response is due to a polyclonal proliferation of fibroblasts which has been attributed to the release of mesenchymal growth factors such as platelet-derived growth factor and transforming growth factor-beta from the abnormal megakaryocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25064?source=see_link\">",
"     \"Pathogenetic mechanisms in primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this may not be the entire mechanism. Overexpression of the thrombopoietin gene using adenovectors in SCID mice (severe combined immune deficient) results in thrombocytosis, increased marrow megakaryocytes, fibrosis, and extramedullary hematopoiesis that mimics primary myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/104\">",
"     104",
"    </a>",
"    ]. However, similar overexpression of thrombopoietin in NOD-SCID mice (which have reduced monocyte and macrophage function in addition to the lymphocyte deficiency in SCID mice) produced similar thrombocytosis and megakaryocytosis but no fibrosis. These results imply that other",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    mediators may be involved in causing the fibrosis which does not result solely from thrombocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Myelodysplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both thrombocytopenia and thrombocytosis may be seen in the myelodysplastic syndromes, findings that have been attributed to abnormal megakaryocytes. The morphologic picture consists of an increased number of small megakaryocytes of low ploidy, occasionally displaying a characteristic \"pawn ball\" nucleus with three lobes (",
"    <a class=\"graphic graphic_picture graphicRef59897 \" href=\"UTD.htm?14/52/15173\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet kinetic studies have demonstrated a greatly expanded megakaryocyte mass (increased number of megakaryocytes of low ploidy) and ineffective platelet production from the megakaryocytes (",
"    <a class=\"graphic graphic_figure graphicRef57865 \" href=\"UTD.htm?30/60/31694\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74204 \" href=\"UTD.htm?6/13/6367\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/22/4458/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in the 5q- syndrome, platelet production may be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359933#H359933\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS with isolated del(5q)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12549620\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Megakaryocytes normally account for 0.05 to 0.1 percent of all nucleated bone marrow cells. They have an average diameter of 20 to 25 microns and a volume of 4700 &plusmn; 100 fL (",
"    <a class=\"graphic graphic_picture graphicRef50650 \" href=\"UTD.htm?28/8/28804\">",
"     picture 2",
"    </a>",
"    ). Each megakaryocyte is capable of producing 1000 to 3000 platelets. Mature megakaryocytes are invariably polyploid and contain from two (4N) to 32 (64N) times the normal diploid amount of DNA. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Origin and differentiation",
"      </strong>",
"      &mdash; Megakaryocytes are derived from the pluripotential stem cell (",
"      <a class=\"graphic graphic_figure graphicRef74886 \" href=\"UTD.htm?24/60/25550\">",
"       figure 1",
"      </a>",
"      ), which gives rise to early progenitors able to undergo erythrocyte or megakaryocyte differentiation. A micro RNA miR-150 drives differentiation towards megakaryocytes. A number of factors affect this differentiation process, including thrombopoietin (TPO), GATA-1, and NF-E2. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Origin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differentiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Platelet formation and regulation",
"      </strong>",
"      &mdash; Cytoskeletal reorganization within the megakaryocyte produces pseudopods by evagination of the demarcation membrane system. Platelet granules then track into the elongating pseudopodia, and proplatelet fragments are extruded into the circulation where they are transformed into mature platelets. TPO produced by the liver enters the circulation where most is removed by TPO receptors (c-mpl) on normal platelets. Residual TPO provides basal stimulation of megakaryocytes and a basal rate of platelet production. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Platelet formation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Regulation of platelet production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Altered megakaryocyte function",
"      </strong>",
"      &mdash; A number of disorders and clinical settings affect the megakaryocyte and platelet production. These are discussed in the text as well as in other sections of UpToDate dealing with the specific disorders mentioned. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Megakaryocytes in disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/1\">",
"      Wright, JH. The origin and nature of blood plates. Boston Medical and Surgical Journal 1906; 154:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/2\">",
"      Wright JH. The histogenesis of the blood platelets. J Morphol 1910; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/3\">",
"      Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/4\">",
"      Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008; 111:981.",
"     </a>",
"    </li>",
"    <li>",
"     Levin J. The evolution of mammalian platelets. In: Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, Kuter DJ, Hunt P, Sheridan W, et al (Eds), Humana Press, Totowa 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/6\">",
"      Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/7\">",
"      Kuter DJ, Greenberg SM, Rosenberg RD. Analysis of megakaryocyte ploidy in rat bone marrow cultures. Blood 1989; 74:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/8\">",
"      Jackson CW, Brown LK, Somerville BC, et al. Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. Blood 1984; 63:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/9\">",
"      Raslova H, Roy L, Vourc'h C, et al. Megakaryocyte polyploidization is associated with a functional gene amplification. Blood 2003; 101:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/10\">",
"      Raslova H, Kauffmann A, Sekka&iuml; D, et al. Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood 2007; 109:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/11\">",
"      Berridge MV, Ralph SJ, Tan AS. Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb-IIIa glycoprotein complex. Blood 1985; 66:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/12\">",
"      Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood 2004; 104:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/13\">",
"      Radley JM, Haller CJ. The demarcation membrane system of the megakaryocyte: a misnomer? Blood 1982; 60:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/14\">",
"      Behnke O. An electron microscope study of the megacaryocyte of the rat bone marrow. I. The development of the demarcation membrane system and the platelet surface coat. J Ultrastruct Res 1968; 24:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/15\">",
"      MacPherson GG. Changes in megakaryocyte development following thrombocytopenia. Br J Haematol 1974; 26:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/16\">",
"      Schulze H, Korpal M, Hurov J, et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood 2006; 107:3868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/17\">",
"      Greenberg SM, Kuter DJ, Rosenberg RD. In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. J Biol Chem 1987; 262:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/18\">",
"      Handagama P, Bainton DF, Jacques Y, et al. Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet alpha-granules. J Clin Invest 1993; 91:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/19\">",
"      Handagama PJ, Amrani DL, Shuman MA. Endocytosis of fibrinogen into hamster megakaryocyte alpha granules is dependent on a dimeric gamma A configuration. Blood 1995; 85:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/20\">",
"      Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/21\">",
"      Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 1989; 84:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/22\">",
"      White JG. Serotonin storage organelles in human megakaryocytes. Am J Pathol 1971; 63:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/23\">",
"      Schick PK, Weinstein M. A marker for megakaryocytes: serotonin accumulation in guinea pig megakaryocytes. J Lab Clin Med 1981; 98:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/24\">",
"      Odell TT Jr, Jackson CW. Polyploidy and maturation of rat megakaryocytes. Blood 1968; 32:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/25\">",
"      Mazur EM, Hoffman R, Chasis J, et al. Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 1981; 57:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/26\">",
"      Poujol C, Tronik-Le Roux D, Tropel P, et al. Ultrastructural analysis of bone marrow hematopoiesis in mice transgenic for the thymidine kinase gene driven by the alpha IIb promoter. Blood 1998; 92:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/27\">",
"      Tronik-Le Roux D, Roullot V, Schweitzer A, et al. Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by the platelet glycoprotein alpha IIb promoter. J Exp Med 1995; 181:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/28\">",
"      Tropel P, Roullot V, Vernet M, et al. A 2.7-kb portion of the 5' flanking region of the murine glycoprotein alphaIIb gene is transcriptionally active in primitive hematopoietic progenitor cells. Blood 1997; 90:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/29\">",
"      Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA. Transcription factor GATA-1 in megakaryocyte development. Stem Cells 1998; 16 Suppl 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/30\">",
"      de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/31\">",
"      Edelstein LC, Bray PF. MicroRNAs in platelet production and activation. Blood 2011; 117:5289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/32\">",
"      Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/33\">",
"      Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008; 36:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/34\">",
"      Miyazaki H, Inoue H, Yanagida M, et al. Purification of rat megakaryocyte colony-forming cells using a monoclonal antibody against rat platelet glycoprotein IIb/IIIa. Exp Hematol 1992; 20:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/35\">",
"      Levene RB, Lamaziere JM, Broxmeyer HE, et al. Human megakaryocytes. V. Changes in the phenotypic profile of differentiating megakaryocytes. J Exp Med 1985; 161:457.",
"     </a>",
"    </li>",
"    <li>",
"     Nakeff A. Colony-forming unit, megakaryocyte (CFU-m): Its use in elucidating the kinetics and humoral control of the megakaryocytic committed progenitor cell compartment. In: Experimental Hematology Today, Baum SJ, Ledney DG (Eds), Springer, New York 1977. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/37\">",
"      Broudy VC, Lin NL, Fox N, et al. Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Blood 1996; 88:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/38\">",
"      Dolzhanskiy A, Basch RS, Karpatkin S. The development of human megakaryocytes: III. Development of mature megakaryocytes from highly purified committed progenitors in synthetic culture media and inhibition of thrombopoietin-induced polyploidization by interleukin-3. Blood 1997; 89:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/39\">",
"      Nagata Y, Muro Y, Todokoro K. Thrombopoietin-induced polyploidization of bone marrow megakaryocytes is due to a unique regulatory mechanism in late mitosis. J Cell Biol 1997; 139:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/40\">",
"      Zimmet JM, Ladd D, Jackson CW, et al. A role for cyclin D3 in the endomitotic cell cycle. Mol Cell Biol 1997; 17:7248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/41\">",
"      Zhang Y, Wang Z, Liu DX, et al. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem 1998; 273:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/42\">",
"      Zimmet JM, Toselli P, Ravid K. Cyclin D3 and megakaryocyte development: exploration of a transgenic phenotype. Stem Cells 1998; 16 Suppl 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/43\">",
"      Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 1997; 90:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/44\">",
"      Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000; 96:4142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/45\">",
"      Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996; 95:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/46\">",
"      Fujiwara Y, Browne CP, Cunniff K, et al. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A 1996; 93:12355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/47\">",
"      Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 2005; 106:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/48\">",
"      Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/49\">",
"      Huang Z, Richmond TD, Muntean AG, et al. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest 2007; 117:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/50\">",
"      Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A 1995; 92:8690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/51\">",
"      Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/52\">",
"      Lecine P, Villeval JL, Vyas P, et al. Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood 1998; 92:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/53\">",
"      Becker RP, De Bruyn PP. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am J Anat 1976; 145:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/54\">",
"      Tong M, Seth P, Penington DG. Proplatelets and stress platelets. Blood 1987; 69:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/55\">",
"      Lecine P, Shivdasani RA. Cellular and molecular biology of megakaryocyte differentiation in the absence of lineage-restricted transcription factors. Stem Cells 1998; 16 Suppl 2:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/56\">",
"      YAMADA E. The fine structure of the megakaryocyte in the mouse spleen. Acta Anat (Basel) 1957; 29:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/57\">",
"      De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/58\">",
"      Lecine P, Blank V, Shivdasani R. Characterization of the hematopoietic transcription factor NF-E2 in primary murine megakaryocytes. J Biol Chem 1998; 273:7572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/59\">",
"      Thon JN, Italiano JE. Platelet formation. Semin Hematol 2010; 47:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/60\">",
"      Lane WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000; 96:4152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/61\">",
"      Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/62\">",
"      Kaufman RM, Airo R, Pollack S, Crosby WH. Circulating megakaryocytes and platelet release in the lung. Blood 1965; 26:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/63\">",
"      Trowbridge EA, Martin JF, Slater DN. Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res 1982; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/64\">",
"      Pedersen NT. Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand J Haematol 1978; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/65\">",
"      Levine RF, Eldor A, Shoff PK, et al. Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol 1993; 51:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/66\">",
"      Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002; 99:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/67\">",
"      Kuter DJ. The physiology of platelet production. Stem Cells 1996; 14 Suppl 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/68\">",
"      BRECHER G, CRONKITE EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/69\">",
"      Giles C. The platelet count and mean platelet volume. Br J Haematol 1981; 48:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/70\">",
"      Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol 1981; 76:289.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson CB. From precursor to product; how do megakaryocytes produce platelets. In: Megakaryocyte Development and Function, Levine RF, Williams N, Levin J, et al (Eds), Liss, New York 1986. p.361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/72\">",
"      von Behrens WE. Evidence of phylogenetic canalisation of the circulating platelet mass in man. Thromb Diath Haemorrh 1972; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/73\">",
"      Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia. J Clin Invest 1966; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/74\">",
"      de Gabriele G, Penington DG. Regulation of platelet production: \"Hypersplenism\" in the experimental animal. Br J Haematol 1967; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/75\">",
"      Aster RH. Studies of the mechanism of \"hypersplenic\" thrombocytopenia in rats. J Lab Clin Med 1967; 70:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/76\">",
"      Penington DG, Olsen TE. Megakaryocytes in states of altered platelet production: cell numbers, size and DNA content. Br J Haematol 1970; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/77\">",
"      Kuter DJ, Rosenberg RD. Regulation of megakaryocyte ploidy in vivo in the rat. Blood 1990; 75:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/78\">",
"      Zeuner A, Signore M, Martinetti D, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007; 67:4767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/79\">",
"      Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/80\">",
"      Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106:3777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/81\">",
"      Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000; 40:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/82\">",
"      Bertino AM, Qi XQ, Li J, et al. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003; 43:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/83\">",
"      Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/84\">",
"      Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/85\">",
"      Penington DG. Studies of platelet production and sequestration in the experimental animal. Proc R Soc Med 1968; 61:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/86\">",
"      Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/87\">",
"      Harker LA. Kinetics of thrombopoiesis. J Clin Invest 1968; 47:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/88\">",
"      Harker LA. Regulation of thrombopoiesis. Am J Physiol 1970; 218:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/89\">",
"      Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/90\">",
"      McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/91\">",
"      Li S, Wang L, Zhao C, et al. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007; 139:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/92\">",
"      Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol 2008; 9:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/93\">",
"      Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/94\">",
"      Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/95\">",
"      Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010; 115:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/96\">",
"      Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/97\">",
"      Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/98\">",
"      Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/99\">",
"      Jacobsson S, Carneskog J, Ridell B, et al. Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol 1996; 56:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/100\">",
"      Pitcher L, Taylor K, Nichol J, et al. Thrombopoietin measurement in thrombocytosis: dysregulation and lack of feedback inhibition in essential thrombocythaemia. Br J Haematol 1997; 99:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/101\">",
"      Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90:4031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/102\">",
"      Li J, Xia Y, Kuter DJ. Analysis of the thrombopoietin receptor (MPL) on platelets from normal and essential thrombocythemic (ET) patients (abstract). Blood 1996; 88:545a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/103\">",
"      Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/104\">",
"      Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/105\">",
"      Rosenthal DS, Moloney WC. Refractory dysmyelopoietic anemia and acute leukemia. Blood 1984; 63:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/22/4458/abstract/106\">",
"      Kobayashi Y, Ozawa M, Maruo N, Kondo M. Megakaryocytic ploidy in myelodysplastic syndromes. Leuk Lymphoma 1993; 9:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6672 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.196.66.12-20F8DF7B33-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4458=[""].join("\n");
var outline_f4_22_4458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12549620\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surface membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific platelet granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microscopic appearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GATA-1 transcription factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NF-E2 transcription factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PLATELET FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      REGULATION OF PLATELET PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MEGAKARYOCYTES IN DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pernicious anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congestive splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immune thrombocytopenic purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reactive thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12549620\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6672|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/60/25550\" title=\"figure 1\">",
"      Megakaryocyte development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/27/16829\" title=\"figure 2\">",
"      Megakaryocyte ploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/25/33181\" title=\"figure 3\">",
"      TPO or c Mpl deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/17/18718\" title=\"figure 4\">",
"      Platelet count and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/60/31694\" title=\"figure 5\">",
"      Megakaryocyte number and volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/32/30222\" title=\"figure 6\">",
"      Megak mass platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/13/6367\" title=\"figure 7\">",
"      Platelet production per nucleus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6672|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24402\" title=\"picture 1\">",
"      Megakaryocytes and platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/8/28804\" title=\"picture 2\">",
"      Bone marrow megakaryocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/29/37335\" title=\"picture 3\">",
"      Demarcation membrane system EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/26/24993\" title=\"picture 4\">",
"      Proplatelet processes EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/8/20614\" title=\"picture 5\">",
"      Megakaryocyte responsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/52/15173\" title=\"picture 6\">",
"      MDS abnormal megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32892\" title=\"table 1\">",
"      Causes reactive thrombocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25064?source=related_link\">",
"      Pathogenetic mechanisms in primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=related_link\">",
"      Physiology of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_22_4459="Screen quest GUNS";
var content_f4_22_4459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Violence victims screening questions: GUNS mnemonic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Is there a",
"        <strong>",
"         G",
"        </strong>",
"        un in the household in which the patient lives?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient associate with",
"        <strong>",
"         U",
"        </strong>",
"        sers of drugs or alcohol?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the patient feel the",
"        <strong>",
"         N",
"        </strong>",
"        eed to protect him- or herself?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do any of these",
"        <strong>",
"         S",
"        </strong>",
"        ituations exist: being a witness to violence or being involved in violence?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     The GUNS mnemonic is a product of the Handgun Epidemic Lowering Plan (HELP) Children's Memorial Hospital, Chicago.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4459=[""].join("\n");
var outline_f4_22_4459=null;
var title_f4_22_4460="Pound tables 2003";
var content_f4_22_4460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Updated metastasis-free survival at 3, 5, and 7 years after a postprostatectomy biochemical (PSA) failure in 321 men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Gleason score",
"      </td>",
"      <td colspan=\"4\">",
"       5-7",
"      </td>",
"      <td colspan=\"4\">",
"       8-10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Years to recur",
"      </td>",
"      <td colspan=\"2\">",
"       &gt;2 yr",
"      </td>",
"      <td colspan=\"2\">",
"       &le;2 yr",
"      </td>",
"      <td colspan=\"2\">",
"       &gt;2 yr",
"      </td>",
"      <td colspan=\"2\">",
"       &le;2 yr",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       PSADT, months*",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       &le;10",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       &le;10",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       &le;10",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       &le;10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       3 years",
"      </td>",
"      <td>",
"       92",
"      </td>",
"      <td>",
"       66",
"      </td>",
"      <td>",
"       99",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       57",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       52",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       5 years",
"      </td>",
"      <td>",
"       92",
"      </td>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       83",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       72",
"      </td>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       27",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       7 years",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       57",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PSA: prostate specific antigen; PSADT: PSA doubling time, months; N/A: not available.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eisenberger, MA, et al. Proc ASCO 2003; 22:380a (abstract 1527).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4460=[""].join("\n");
var outline_f4_22_4460=null;
var title_f4_22_4461="Initial coma eval and Rx childr";
var content_f4_22_4461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Emergent evaluation and management of stupor and coma in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       EVALUATION",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vital signs and general and trauma examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurologic examination and GCS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Screening laboratories (CBC, glucose, electrolyes, BUN, creatinine, blood cultures, LFTs, urinalysis, urine drug screen)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head CT scan: do emergently if focal neurologic signs, papilledema, fever - consider rapid MRI instead if available.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lumbar puncture: do emergently after CT scan if fever, elevated WBC, meningismus; otherwise do according to level of suspicion for diagnosis or if cause remains obscure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other laboratory tests: for metabolic conditons (see text), coagulation tests, carboxyhemoglobin, specific drug concentrations - do according to level of suspicion for diagnosis or if cause remains obscure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       EEG: for possible nonconvulsive seizure, or if diagnosis remains obscure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brain MRI with DWI, if cause remains obscure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       MANAGEMENT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       ABCs:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Intubate if GCS &le;8 or respiratory failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stabilize cervical spine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Supplement O2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       IV access",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Blood pressure support as needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Dextrose 0.25 g/kg (2.5 mL/kg of 10 percent dextrose solution) after blood glucose drawn, before results back; do NOT delay pending results",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Treat definite seizures. Initial treatment with lorazepam (0.1 mg/kg, maximum single dose 5 mg). If seizures continue treat as for status epilepticus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Empiric treatments:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       For possible infection:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Ceftriaxone 100 mg/kg (maximum single dose 2 grams) and Vancomycin (age-specific dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Acyclovir (age-specific dose)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       For possible ingestion:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Naloxone 0.1 mg/kg IV in patients up to 20 kg or &le; 5 years; maximum 2 mg IV (use if opioid toxidrome: miosis, respiratory depression, hypotonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       For possible increased ICP:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mannitol 0.5 to 1 gram/kg IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       For possible nonconvulsive status:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Lorazepam (0.1 mg/kg, maximum single dose 5 mg). If suspicion of seizures continue treat as for status epilepticus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Fosphenytoin (10 to 20 PE equivalents/kg). If suspicion of seizures continue treat as for status epilepticus.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GCS: Glasgow coma scale; CBC: complete blood count; BUN: blood urea nitrogen; PT: prothrombin time; PTT: partial thromboplastin time; ABG: arterial blood gas; LFT: liver function tests; ECG: electrocardiogram; CT: computed tomography; WBC: white blood cells; EEG: electroencephalography; MRI: magnetic resonance imaging; DWI: diffusion weighted imaging; ICP: intracranial pressure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4461=[""].join("\n");
var outline_f4_22_4461=null;
var title_f4_22_4462="Contents: Radiation therapy";
var content_f4_22_4462=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Radiation therapy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Radiation therapy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Radiation biology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4106\">",
"           Biology and clinical features of radiation injury in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/17/38170\">",
"           Treatment of radiation injury in the adult",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Techniques",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32630\">",
"           Intensity-modulated radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/45/10968\">",
"           Proton and ion beams in cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33924\">",
"           Radiation therapy for the management of painful bone metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17143\">",
"           Stereotactic body radiation therapy for primary and metastatic lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/21/43350\">",
"           Stereotactic body radiation therapy: Rationale and clinical experience",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32855\">",
"           Stereotactic cranial radiosurgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Toxicity and complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/29/25049\">",
"           Clinical features, diagnosis, and treatment of radiation proctitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/46/17129\">",
"           Clinical manifestations and treatment of radiation-induced fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37226\">",
"           Complications of cranial irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2566\">",
"           Complications of cranial stereotactic radiosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38437\">",
"           Complications of peripheral nerve irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7190\">",
"           Complications of spinal cord irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/42/20137\">",
"           Gastrointestinal toxicity of radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/33/24090\">",
"           Radiation-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/49/1818\">",
"           Radiation-induced thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/48/3847\">",
"           Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DDB96A3DB5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_22_4462=[""].join("\n");
var outline_f4_22_4462=null;
var title_f4_22_4463="Approach to tachycardia";
var content_f4_22_4463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Approach to tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_22_4463=[""].join("\n");
var outline_f4_22_4463=null;
